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A B S T R A C T
Background
Chronic bronchitis and chronic obstructive pulmonary disease (COPD) are serious conditions in which patients are predisposed to viral
and bacterial infections resulting in potentially fatal acute exacerbations. COPD is defined as a lung disease characterised by obstruction
to lung airflow that interferes with normal breathing. Antibiotic therapy has not been particularly useful in eradicating bacteria such as
non-typeable Haemophilus influenzae (NTHi) because they are naturally occurring flora of the upper respiratory tract in many people.
However, they can cause opportunistic infection. An oral NTHi vaccine has been developed to protect against recurrent infective acute
exacerbations in chronic bronchitis.
Objectives
To assess the effectiveness of an oral, whole-cell, non-typeable H. influenzae (NTHi) vaccine in protecting against recurrent episodes
of acute exacerbations of chronic bronchitis and COPD in adults. To assess the effectiveness of NTHi vaccine in reducing NTHi
colonising the respiratory tract during recurrent episodes of acute exacerbations of COPD.
Search methods
We searched the following databases: CENTRAL (2014, Issue 6), MEDLINE (1946 to July week 3, 2014), EMBASE (1974 to July
2014), CINAHL (1981 to July 2014), LILACS (1982 to July 2014) and Web of Science (1955 to July 2014). We also searched trials
registries and contacted authors of trials requesting unpublished data.
Selection criteria
We included randomised controlled trials comparing the effects of an oral monobacterial NTHi vaccine in adults with recurrent acute
exacerbations of chronic bronchitis or COPD when there was overt matching of the vaccine and placebo groups on clinical grounds.
The selection criteria considered populations aged less than 65 years and those older than 65 years.
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Data collection and analysis
Two authors independently assessed trial quality and extracted data from original records and publications for incidence and severity
of bronchitis episodes and carriage rate of NTHi measured in the upper respiratory tract, as well as data relevant to other primary and
secondary outcomes.
Main results
We identified six placebo-controlled randomised controlled trials with a total of 557 participants. They investigated the efficacy of
enteric-coated, killed preparations of H. influenzae in populations prone to recurrent acute exacerbations of chronic bronchitis or
COPD. The vaccine preparation and immunisation regime in all trials consisted of at least three courses of formalin-killedH. influenzae
in enteric-coated tablets taken at intervals (for example, days 0, 28 and 56). Each course generally consisted of two tablets taken after
breakfast over three consecutive days. In all cases the placebo groups took enteric-coated tablets containing glucose. Risk of bias was
moderate across the studies, namely due to the lack of information provided about methods and inadequate presentation of results.
Meta-analysis of the oral NTHi vaccine showed a small, non-statistically significant reduction in the incidence of acute exacerbations
of chronic bronchitis or COPD by 2.048% (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.84 to 1.12, P value = 0.68). There
was no significant difference in mortality rate between the vaccine and placebo groups (odds ratio (OR) 1.62, 95% CI 0.63 to 4.12, P
value = 0.31).
We were unable to meta-analyse the carriage levels of NTHi in participants as each trial reported this result using different units and
tools of measurement. Four trials showed no significant difference in carriage levels, while two trials showed a significant decrease in
carriage levels in the vaccinated group compared with placebo.
Four trials assessed severity of exacerbations measured by requirement for antibiotics. Three of these trials were comparable and when
meta-analysed showed a statistically significant 80% increase in antibiotic courses per person in the placebo group (RR 1.81, 95% CI
1.35 to 2.44, P value < 0.0001). There was no significant difference between the groups with regards to hospital admission rates (OR
0.96, 95% CI 0.13 to 7.04, P value = 0.97). Adverse events were reported in all six trials with a point estimate suggestive that they
occurred more frequently in the vaccine group, however, this result was not statistically significant (RR 1.43, 95% CI 0.70 to 2.92, P
value = 0.87). Quality of life was not meta-analysed but was reported in two trials, with results at six months showing an improvement
in quality of life in the vaccinated group (scoring at least two points better than placebo).
Authors’ conclusions
Analyses demonstrate that NTHi oral vaccination of patients with recurrent exacerbations of chronic bronchitis or COPD does not
yield a significant reduction in the number and severity of exacerbations. Evidence is mixed and the individual trials that show a
significant benefit of the vaccine are too small to advocate widespread oral vaccination of people with COPD.
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Review question
We reviewed the evidence about the effect of a non-typeable Haemophilus influenzae (H. influenzae) (NTHi) vaccine in preventing
repeated H. influenzae infections in people with chronic obstructive pulmonary disease (COPD) or chronic bronchitis.
Background
People with COPD can often have frequent infections that worsen symptoms of their lung disease, that is increased breathlessness,
purulent discharge and decompensating oxygen saturations levels, known as an ’acute exacerbation’. The most common bacteria that
causes this is H. influenzae; it can lead to hospitalisation and sometimes death. If these infections can be prevented with a vaccine,
people with COPD may have improved outcomes compared to the current practice of treating infections as they arise.
Study characteristics
The evidence is current to July 2014. We identified six studies with 557 participants. The studies were blinded, placebo-controlled
randomised trials that tested how effective the NTHi vaccine is in preventing infections in people aged over 18 years with COPD or
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chronic bronchitis. In all six trials, both the vaccine and placebo group were given at least three courses of tablets at regular intervals
over a period of three to 12 months. Generally the baseline demographics of participants across the included studies shared similar
characteristics (such as diet, lifestyle and living conditions) to other high-income countries. Ages ranged between 40 and 80 years. The
studies counted the number of infections the participants experienced, levels of respiratory tract bacteria, deaths, side effects, hospital
admissions or treatment with antibiotics.
Key results
TheNTHi vaccine has no significant impact on reducing the number of infections COPDpatients experience. There was no significant
difference in mortality rate between the vaccine and placebo groups and the reported deaths in the vaccinated group were not attributed
to the vaccine.
The levels of H. influenzae bacteria found in the respiratory tracts of participants was not significantly different between the vaccine
and placebo groups. Due to inconsistencies of measurement between the trials, we were not able to compare the studies against one
another.
Antibiotics, which can be an indicator of severe infection, were significantly more commonly prescribed in the placebo group. Evidence
of hospital admissions showed that there was no difference in the likelihood of being hospitalised in either the vaccine or placebo
group. Two trials studying quality of life found that vaccinated participants generally had a better quality of life, but these results were
measured differently and so could not be compared.
Adverse effects were not reported nor clearly defined amongst the trials. Five trials reported adverse effects but there was no particular
association with either the vaccine or placebo group. Further research is needed to define adverse effects as outcome measures for more
definitive analyses regarding vaccine side effects.
Quality of the evidence
The studies were well conducted with moderate risk of bias. The main limitation of this review was the lack of consistency regarding the
definitions and outcome measures among the individual studies, which affected the overall synthesis and interpretation of the results.
Fewer participants may cause the results to be more likely to be affected by chance. One trial had more participants than the other five
combined and it contributed more to the final analysis. There was moderate heterogeneity (the studies show quite different results)
when this study was included in the analysis, especially in numbers of infections. However, the results are consistent and do not change
if this study is removed from the analysis.
Conclusion
We concluded after reviewing the relevant studies that the H. influenzae vaccine taken orally in people with chronic bronchitis and
COPD does not have a significant reduction in the number and severity of acute exacerbations.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Haemophilus influenzae oral vaccination for prevention of acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD)
Patient or population: adults (>18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
Settings: community and outpatients
Intervention: oral monobacterial vaccination with killed NTHi
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk
Not vaccinated
Corresponding risk
NTHi oral vaccinated
Acute exacerbations
(number of exacerba-
tions/person/year)
2.111 exacerbations per
person/year
1.633 exacerbations
per person/year
RR 0.97
(0.84 to 1.12)
557
(6)
⊕⊕⃝⃝
low1
Despite an absolute es-
timated decrease in the
rate of exacerbations in
the vaccinated group, the
result is negligible (95%
CI crosses 1.00) and not
statistically significant (P
value = 0.68)
Mortality
(deaths during trial pe-
riod)
23 per 1000 37 per 1000
(15 to 88)
OR 1.62
(0.63 to 4.12)
518
(5)
⊕⃝⃝⃝
very low2
Despite more absolute
deaths occurring in the
vaccinated group, the re-
sult is negligible (95% CI
crosses 1.00) and not
statistically significant (P
value = 0.31). Deaths
were not necessarily at-
tributed to the use of the
vaccine
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Carriage of NTHi
Not meta-analysed
N/A N/A N/A N/A ⊕⃝⃝⃝
very low6
We were unable to meta-
analyse the carriage lev-
els of NTHi in partici-
pants as each trial re-
ported this result using
different units and tools
of measurement. 4 trials
showed no significant dif-
ference in carriage lev-
els, while 2 trials showed
a significant decrease in
carriage levels in the vac-
cinated group compared
with the placebo group
Antibiotic prescriptions
(number of courses/per-
son/year)
**Corticosteroids not
meta-analysed
6.198
prescriptions
per person/year
3.162
prescriptions
per person/year
RR 1.81
(1.35 to 2.44)
142
(3)
⊕⊕⃝⃝
low3
Courses of antibiotics
were found to be pre-
scribed in the placebo
group at a rate approxi-
mately 80% greater than
the vaccinated group (P
value <0.0001)
(Please note that a RR
> 1.0 here indicates
more antibiotics being
prescribed to participants
in the placebo group; that
is, RR 1.81 corresponds
to an approximately 80%
increased rate of antibi-
otic prescriptions when
not receiving the vaccine.
The placebo group is be-
ing compared to the vac-
cine in this instance to
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attempt to demonstrate
how many more antibi-
otics are required in those
not vaccinated)
**2studies reported corti-
costeroid use, however due
to differences in units of
measurement, these results
could not bemeta-analysed
Hospital admissions
(number of patients hos-
pitalised during trial pe-
riod)
311 per 1000 466 per 1000
(359 to 570)
OR 0.96
(0.13 to 7.04)
358
(2)
⊕⊕⊕⃝
moderate4
The difference in the
likelihood of being hos-
pitalised was found to
be negligible (95% CI
crosses 1.00) between
the 2 groups (P value =
0.01)
(Significant heterogene-
ity was also noted with
this result (I2 = 84%)
; there may be un-
known and unmeasured
factors contributing to
hospitalisations; we used
the random-effectsmodel
for analysis here, versus
the fixed-effect model for
non-heterogenous data)
Adverse events
(number of adverse
events/person/year)
0.319
adverse events
per person/year
0.430
adverse events
per person/year
RR 1.43
(0.70 to 2.92)
484
(4)
⊕⊕⃝⃝
low5
Despite an estimated ab-
solute increased rate of
adverse events in the vac-
cinated group, the re-
sult is negligible (95% CI
crosses 1.00) and not
statistically significant (P
value = 0.61). Adverse
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events were not neces-
sarily attributable to the
vaccine
Quality of life
Not meta-analysed
N/A N/A N/A N/A ⊕⃝⃝⃝
very low6
Quality of life was not
meta-analysed due to dif-
fering units of measure-
ment, but was reported in
2 trials, which showed an
improvement at 6 months
in the vaccine group
(scoring at least 2 points
better than the placebo
group; significance un-
known)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% confidence interval (CI)) is based on
the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; NTHi: non-typeable Haemophilus influenzae; OR: odds ratio; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1One study had marked heterogeneity; most studies had a low number of participants; one study had significant attrition.
2Mortality was not formally measured; five studies reported on deaths but none attributed to vaccine.
3Only three studies recorded information on prescriptions; studies had a low number of participants; method of allocation concealment
and randomisation was unclear in two of the studies.
4Only two studies recorded information of hospitalisations; one study was significantly larger than the other.
5Most studies had a low number of participants; one study may have had attrition bias; two studies had high risk of bias for randomisation
and allocation concealment.
6Meta-analysis was not performed; inconsistent units of measurement used by studies, therefore not comparable.
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B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is characterised
by persistent airflow limitation that is progressive and associated
with an enhanced chronic inflammatory response. The chronic
airflow limitation characteristic of COPD is caused by amixture of
small airways disease (obstructive bronchiolitis) and gas-exchange
impediment through parenchymal destruction (emphysema). The
changes associated with an inflammatory response include cellular
infiltrate, mucus secretion and structural remodelling, which di-
minishes the overall ability of the airways to remain patent during
expiration. This limitation in airflow, as a measurement of disease
severity, is best measured and assessed by spirometry (COPD is
defined as the forced expiratory volume in one second (FEV1)
being lower than 80% of the predicted normal) (GOLD 2011;
Otczyk 2011).
Chronic bronchitis is defined clinically by the presence of cough
and sputum production for at least three months in each of two
consecutive years. It is an independent disease entity which may
precede or follow the development of airflow limitation and may
be associated with development and/or acceleration of fixed air-
flow limitation, that is, COPD. Chronic bronchitis may exist in
patients with normal spirometry (GOLD 2011). While patients
can remain undiagnosed and have no clinical evidence of a lung
disease until they present with advanced COPD, many have a
history of symptomatic disease, evidenced as chronic cough and
sputum (chronic bronchitis) and/or recurrent episodes of acute
wheezy bronchitis and/or late onset reversible airways disease (in-
trinsic asthma). Currently, the diagnosis of an acute exacerbation
is based entirely on clinical presentation. There is no consensus
regarding an objective measurement of an exacerbation (GOLD
2011). The relationship between these entities is complex and not
well understood, with no obligatory linkage with COPD but has
the capacity to progress to COPD (Otczyk 2011).
An acute exacerbation is defined as an acute event characterised by
worsening of the patient’s respiratory symptoms beyond normal
daily variations and can lead to a change in medication (GOLD
2011). The best predictors of exacerbations are a history of pre-
viously treated exacerbations and worsening airflow limitation
(GOLD 2011). They may be triggered by bacterial or viral in-
fection (or both simultaneously), environmental pollutants or as
yet undetermined factors. The characteristic response is increased
inflammation resulting in increased purulent sputum production,
hyperinflation and gas trapping, with reduced expiratory flow,
thus accounting for the dyspnoea associated with these episodes
(GOLD 2011). Whilst participants with an atopic constitution
(hypersensitive to allergens) may have a predisposition to develop
COPD, it should be recognised that bacterial colonisation of dam-
aged airways plays an important pathogenic role. In participants
with established obstructive lung disease, acute attacks of infection
are a major cause of morbidity and mortality.
The GOLD guidelines estimate the prevalence of COPD to range
from 7.8% to 19.7% of the population worldwide (GOLD 2011).
COPD is very prominent in populations of smokers and ex-smok-
ers. However, estimates of prevalence in people who have never
smoked range from3% to 11% (GOLD 2011). TheWorldHealth
Organization (WHO) estimates 5% of all deaths globally can be
attributed to COPD, with the disease becoming the third leading
cause of death by 2030 (WHO 2013). Whilst epidemiological in-
formation regarding COPD comes from high-income countries,
90% of COPD deaths occur in low and middle-income countries
(WHO 2013).
The management of acute exacerbations focuses on treating trig-
gers (including infections) and relieving symptoms with bron-
chodilators, glucocorticoids and antibiotics. Prevention of further
exacerbations focuses on vaccination of influenza and pneumo-
coccus strains (WHO 2013). A recent Cochrane review on the
use of prophylactic antibiotics for COPDexacerbations concluded
there was a reduction in the number of patients experiencing ex-
acerbations with continuous macrolide antibiotic use. The num-
ber needed to treat to prevent one exacerbation was eight. These
promising findings need to be weighed against the risks from long-
term antibiotic use such as side effects of medications and bacterial
resistance (Herath 2013).
Bacterial and viral causative agents have been identified and may
coexist in a benign or pathogenic capacity; because of this, the spe-
cific microbiological aetiology of acute exacerbations in chronic
bronchitis and COPD patients remains a matter of debate. The
pathogens responsible for these acute exacerbations are often found
in the participant’s upper respiratory tract and (opportunistic) in-
fections are caused by an upset in the balance of the host-par-
asite relationship. Bacterial colonisation is most common and
more severe compared to viral infections. The upper respiratory
tract is commonly home to Staphylococcus epidermidis (S. epider-
midis),Staphylococcus aureus (S. aureus),Streptococcus pneumoniae
(S. pneumoniae),Streptococcus pyogenes (S. pyogenes),H. influenzae
andNeisseria meningitides (N. meningitides). The lower respiratory
tract is normally virtually free of micro-organisms, due to physio-
logical clearance mechanisms (e.g. mucociliary clearance). How-
ever, should these systems become damaged (as is the case in
COPD or bronchitis patients), pathogens such as non-typeableH.
influenzae (NTHi) or Pseudomonas aeruginosa (P. aeruginosa) are
usually the ones to colonise these sites (Butt 1990). NTHi is of
particular importance in this scenario because of its frequent and
predominant pattern of mucosal colonisation of the respiratory
tract.Higher levels of Immunoglobulin E (IgE) have been detected
in the serum of patients with COPD and it has been observed
that NTHi triggers histamine release. This process occurs through
both IgE- and non-IgE-dependent mechanisms from cells con-
tained within the respiratory mucosal sensitised to the bacterium.
These findings demonstrate that NTHi may also play a role in the
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development of the reversible component of airways obstruction
in COPD. Immediate hypersensitivity via IgE anti-bacterial anti-
bodies to colonising bacteria may contribute to bronchial disease
progression and severity (Otczyk 2011). As these conditions have
been associated with high numbers of NTHi, the vaccine was con-
sidered to be relevant in prevention of exacerbation frequency and
severity.
Description of the intervention
Various treatment strategies have been attempted including im-
muno-stimulatory agents made from bacterial extracts, such as
OM-85 BV, and antibiotics. While OM-85 BV appears not to af-
fect the occurrence of acute exacerbations of bronchitis, it reduces
the severity of the exacerbation (55% less total days of hospitali-
sation compared to placebo) (Collet 1997). Conventional antibi-
otic therapy has not been particularly helpful, possibly due to the
inability to effectively clear respiratory flora such as NTHi that
leads to further growth and sepsis (Foxwell 1998; Murphy 1992;
Van Alphen 1995). Recent studies have identified a role for antibi-
otics in the treatment of COPD (Albert 2011; Macfarlane 2001).
Although significant differences in the incidence of exacerbation
were noted between groups, the long-term effect on microbial re-
sistance was not reported. This underscores the importance of ex-
ploring vaccination as a prophylactic treatment of COPD.
An alternative strategy is mucosal immunisation. Successful vac-
cines for H. influenzae depend on immunity stimulation against
the type-specific polysaccharide capsule ofHaemophilus influenzae
B (Hib). Following the development of successful vaccines for in-
fections caused by Hib, attention is now focused on developing a
vaccine for NTHi. Accordingly, an oral, whole-cell NTHi vaccine
has been developed to preventNTHi infections, which is the focus
of this review.
Oral immunisation reduced bacterial loads in participants who
were chronically colonised and NTHi-specific cellular responses
were detected in white blood cells (lymphocytes) in the serum
(Otczyk 2010). This suggests that a NTHi vaccine may be useful
as it demonstrates that mucosal immunisation can be used thera-
peutically to enhance or modify an immune response to improve
the outcomes of an established chronic mucosal infection (Otczyk
2010).
How the intervention might work
The vaccine is believed to be most effectively absorbed through
the gastrointestinal tract in order to trigger an immune response.
The killed NTHi cells of the vaccine are coated with formalin
to protect it from gastric degradation, thus enabling it to access
the M-cells of the gut mucosal immune system through pattern-
recognition receptors that are designed to identify pathogen-as-
sociated molecular patterns (i.e. PRR-PAMP interactions). Hu-
man and animal studies support the hypothesis that oral NTHi
immunisation stimulates T-cells in the Peyers patches of the gas-
trointestinal tract (Foxwell 1998). The T-cells, upon stimulation
from the vaccine, migrate to the respiratory system via afferent
lymphatics and blood, where they are further stimulated by bac-
teria in the bronchial mucosa. Cytokines are secreted from the
stimulated T-cells to further increase immune activity. This results
in increased recruitment and up-regulation of neutrophil white
blood cells into the bronchial space, which in turn assists in clear-
ing bacteria through phagocytosis and thus reducing the bacterial
load (Clancy 2011).
However, it is to be noted that this form of immunisation does not
trigger classical mucosal Immunoglobulin A (IgA) responses but
rather by the means outlined above. Nonetheless, an oral vaccine
of inactivated NTHi makes use of a ’physiological protective loop’
to improve airway immune function. The vaccine is consumed
orally and digested within the gastrointestinal tract, which triggers
an innate immune response in the respiratory tract. Through a
specific activation of immune cells (in the gastrointestinal tract)
this initiates non-specific protection (in the airways). Pathways
that stimulate T-helper 17 immune cells responsible for airway
protection then generate an increased white blood cell responsive-
ness to all pathogens in the respiratory tract (Clancy 2011).
Why it is important to do this review
COPD is a major cause of morbidity and mortality. Acute exac-
erbations of COPD reflect intense intrabronchial inflammation,
where recurrent exacerbations are linked to worsening of airflow
obstruction and health status of the individual. Acute exacerba-
tions of COPD can be fatal. Recent studies demonstrate that oral
immunotherapy with NTHi reduces the level of bacterial coloni-
sation in the airways as well as the incidence and severity of acute
exacerbations (Otczyk 2011).
Chronic antibiotic therapy is not particularly feasible, so an oral,
whole-cell vaccination for NTHi has been developed to reduce
morbidity andmortality in participants at risk. Clinical benefit has
been reflected in reduced incidence and severity of exacerbations in
a number of studies. A review of trials that use oral NTHi whole-
cell vaccinations should evaluate if oral immunotherapy provides
a significant therapeutic advance in limiting damage in COPD
and may highlight the pathogenic role of bacterial colonisation of
damaged airways.
This is an update of a Cochrane Review first published in 1998
and last updated in 2006 (Foxwell 2006). The previous authors
concluded that participants with recurrent bronchitis vaccinated
in the autumn have a decreased incidence and severity of their
exacerbations during winter.
O B J E C T I V E S
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To assess the effectiveness of an oral, whole-cell, non-typeable H.
influenzae (NTHi) vaccine in protecting against recurrent episodes
of acute exacerbations of chronic bronchitis and COPD in adults.
To assess the effectiveness of NTHi vaccine in reducing NTHi
colonising the respiratory tract during recurrent episodes of acute
exacerbations of COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) investigating the efficacy of
an oral monobacterial NTHi vaccine in people predisposed to
acute exacerbations of chronic bronchitis and COPD.
Types of participants
Adults (18 years or older) with either COPD or recurrent acute
exacerbations of chronic bronchitis.
Types of interventions
All trials comparing a monobacterial NTHi orally administered
vaccine with a placebo. Trialsmay allow the use of bronchodilators,
analgesics and antibiotics to both active and placebo groups.
Types of outcome measures
Primary outcomes
1. Incidence of acute exacerbations of chronic bronchitis or
COPD.
2. Mortality.
Secondary outcomes
1. Carriage level of NTHi in the respiratory tract (including
nasopharyngeal swabs, sputum samples, nasopharyngeal
aspirates).
2. Numbers of prescriptions for antibiotics and corticosteroids
in the trial and follow-up periods (including hospital admissions)
as an indication of severity of acute exacerbations.
3. Any associated adverse side effects from the NTHi
vaccination, measurable from symptomology and participant
reports.
4. Quality of life. A validated tool measurement was required
for trials to be included in this review.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (2014, Issue 6), which includes the Acute Respi-
ratory Infections Group’s Specialised Register, MEDLINE (1946
to July week 3, 2014), EMBASE (1974 to July 2014), CINAHL
(1981 to July 2014), LILACS (1985 to July 2014) and Web of
Science (1955 to July 2014).
We used the search strategy in Appendix 1 to search MED-
LINE and CENTRAL.We combined theMEDLINE search with
the Cochrane Highly Sensitive Search Strategy for identifying
randomised trials in MEDLINE: sensitivity-maximising version
(2008 revision); Ovid format (Lefebvre 2011). We adapted the
search strategy to search EMBASE (see Appendix 2), CINAHL
(see Appendix 3), LILACS (see Appendix 4) and Web of Science
(see Appendix 5).We used no publication or language restrictions.
Searching other resources
We searched the clinical trials registers, WHO International Clin-
ical Trials Registry Platform (ICTRP) (http://www.who.int/ictrp/
en/) and ClinicalTrials.gov (http://clinicaltrials.gov/) for com-
pleted and ongoing trials (last searched 29 July 2014). We also
searched reference lists of included trials and review studies; books
related to respiratory tract infections,mucosal immunology or vac-
cines; abstracts from respiratory conferences, immunology confer-
ences, microbiology conferences or vaccine conferences; and sent
written enquiries to the authors of major relevant studies and ex-
perts in the field. We also contacted pharmaceutical companies to
obtain access to unpublished trials.
Data collection and analysis
Selection of studies
Two review authors (KL, ET) assessed titles and abstracts retrieved
from the search to determine their relevance concerning the ob-
jectives of this review. We managed disagreements through dis-
cussion and/or a deciding arbiter (MVD). We entered all search
results into Review Manager 5.2 (RevMan 2012).
Data extraction and management
Two review authors (HH, SNP) designed a data extraction sheet
for trial reports, which was pilot tested using sample studies and
revised by the other authors. Two review authors (HH, SNP) then
independently extracted data from the reports. We extracted data
from each report separately and then combined data in the event
of multiple reports for the same study.Wemanaged disagreements
through discussion and/or a deciding arbiter (MVD).
10Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary
disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Assessment of risk of bias in included studies
Two review authors (KL, JP) independently analysed each trial in
conjunction with The Cochrane Collaboration’s table for assess-
ing ’Risk of bias’ (Higgins 2011; RevMan 2014): sequence genera-
tion, allocation concealment, blinding, incomplete outcome data,
selective outcome reporting and other potential threats to validity
are domains that we judged each study on. Review authors’ judge-
ments involved rating the risk of bias for each domain as “high” or
“low” or “unclear” whilst providing supporting information that
led to that rating. We managed disagreements through discussion
and/or a deciding arbiter (MVD).
Measures of treatment effect
1. We presented dichotomous (binary) data as a measure of
risk and relative risk by using an odds ratio (OR) or risk ratio
(RR) with 95% confidence intervals (CIs). We calculated the
absolute risk reduction (ARR) for consumer comparison against
other treatments or non-treatment.
2. We presented continuous data as mean differences (MDs) if
the same scale was used or as standardised mean differences
(SMDs) if different scales were used with a standard deviation
(SD) of the estimate.
3. We looked for quality of life (QoL) outcomes as measured
in the included studies. Quality of life measurements had to be
measured using a validated tool. If possible, we pooled these
outcomes but if not, we discussed and summarised them.
4. We have pooled data reported as rates by using the inverse
variance method as described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
Unit of analysis issues
The unit of analysis in our review is the participant.
Dealing with missing data
We contacted the trial authors of the original studies when further
data or information was required. We performed analyses based
on intention-to-treat (ITT), such that we assumed missing data
for randomised participants to be treatment failures in this review.
This ITTanalysismay underestimate the effect of the intervention,
therefore we performed both ITT and on-treatment analyses to
explore the impact of missing data on the overall outcome. We
presented the findings of these analyses in the Discussion section.
Assessment of heterogeneity
We assessed included trials for heterogeneity (which is a varia-
tion in study outcomes amongst the studies as further defined in
Higgins 2011) through two successive steps to determine if they
should be pooled with the rest of the included trials or reported
in a systematic review.
1. Two review authors (KL, JP) independently analysed trials
for their ’face-value’ similarities: that is, for clinical diversity
(participants, interventions and outcomes) and methodological
diversity (study design and risk of bias).
2. We subsequently assessed trials for statistical heterogeneity
using the Chi2 test with a P value of less than 0.10 being
statistically significant. We calculated the I2 statistic as instructed
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011; RevMan 2014). If this was greater than 50% we
considered the pooled trials to be significantly heterogeneous.
Assessment of reporting biases
If a sufficient number of studies had been pooled (i.e. greater than
25), we planned to use a funnel plot to visually inspect the risk
of publication bias, where more pronounced asymmetry of the
funnel plot may be indicative of a substantial overestimation of
the intervention effect (Higgins 2011; RevMan 2014).
Data synthesis
We synthesised the data as follows.
1. We used a fixed-effect model for binary or continuous data
in the absence of statistical heterogeneity (I2 < 50%) according
to the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011; RevMan 2014).
2. We used a random-effects model for binary or continuous
data in the presence of statistical heterogeneity (I2 > 50%) for
pooling the trial data using the Mantel-Haenszel method
according to the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011; RevMan 2014). This model of
analysis will make the assumption that the studies are not
measuring for the same intervention effect, but instead will
consequently estimate for an overall intervention effect that is
trending amongst the studies.
3. We also used the fixed-effect model to pool study data that
reported events as rates according to the Cochrane Handbook for
Systematic Reviews of Interventions; only fixed-effect meta-analysis
methods are available in RevMan for ’O - E and Variance’
outcome (Higgins 2011; RevMan 2014).
Subgroup analysis and investigation of heterogeneity
If sufficient data were available, we planned to explore specific
subgroups for further analyses of treatment effect.
1. Comparison of continued-smoking versus ex-smoking
populations.
2. Younger (< 65 years) versus older (65 years and older)
participants.
Sensitivity analysis
If sufficient data were available, we planned to perform sensitivity
analyses by:
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1. examining how the addition of high risk of bias studies to
low risk of bias studies impacts on the overall outcome to
determine the effects of risk of bias; and
2. examining which studies contribute to heterogeneity and
how this impacts on the overall outcome.
We used different methods of pooling, e.g. initially pooling all
trials and then excluding one-by-one specific trials from the meta-
analysis and comparing the results, whilst also comparing the use of
a fixed-effect versus random-effects model for the pooling analysis.
Otherwise, we entered trials one-by-one into the meta-analysis to
assess the robustness of the pooled estimates.
R E S U L T S
Description of studies
Results of the search
We obtained 105 records from our searches as described in Search
methods for identification of studies. From the search result, we
identified 10 randomised controlled trials (RCTs) which provided
data pertinent to the non-typeable H. influenzae oral vaccine in
preventing acute exacerbations in chronic bronchitis and COPD
(Figure 1).
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Figure 1. Inclusion of trials flow diagram
13Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary
disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
We included six studies in this review (Clancy 1985; Clancy 1990;
Clancy 2013; Lehmann 1991; Tandon 1991; Tandon 2010).
The main features of the included trials are summarised in the
Characteristics of included studies table. The methods are de-
scribed here in greater detail, largely using direct excerpts of the
original papers as these demonstrate the trials’ strengths and weak-
nesses in the words of the original authors.
Overview
All six of the included studies were clinical placebo-controlled
RCTs, five of which were double-blinded (Clancy 1985; Clancy
2013; Lehmann 1991; Tandon 1991; Tandon 2010) and one
was single-blinded (Clancy 1990). They were conducted to test
the efficacy of enteric-coated, killed preparations of H. influenzae
in populations prone to recurrent acute exacerbations of chronic
bronchitis or COPD. The vaccine preparation and immunisation
regime used in all trials consisted of at least three courses of forma-
lin-killed H. influenzae in enteric-coated tablets taken at intervals
(for example, on days 0, 28 and 56). Each course generally con-
sisted of two tablets taken after breakfast over three consecutive
days. In all cases, the placebo groups took enteric-coated tablets
containing glucose.
The trials varied in duration from three to 12 months. Randomi-
sation in the trials was achieved by having a pharmacist indepen-
dently preparing treatment packages that contained either active
or placebo tablets (Clancy 1990; Lehmann 1991; Tandon 1991).
These packages were numbered and randomised before being dis-
tributed to the clinicians involved in the trials, where the phar-
macist was responsible for disclosing the randomised codes at the
conclusion of the trial.
The trials varied in population groups, with most trials includ-
ing chronic bronchitis or COPD patients in Australia with mean
ages between 40 and 80 years (Clancy 1985; Clancy 1990; Clancy
2013; Tandon 1991; Tandon 2010). Lehmann 1991 was con-
ducted in chronic bronchitis or COPD patients in Papua New
Guinea, with a mean age of 51 years.
Bacterial load was assessed by a standardised method across the six
trials.Multiple cultures were performed on each person. In normal
circumstances, the first culture following vaccination was taken at
three months. Cultures were taken at regular three-monthly in-
tervals and extra cultures taken during illness. The method of ob-
taining samples, transporting material and culture methods gen-
erally followed a set protocol for adequate specimen handling and
control. However, the lack of consistency and wide variety of mea-
surement styles used amongst the studies to calculate and report
carriage levels made analyses between studies difficult.
Measured outcomes in the trials were varied but included bacterial
load within the respiratory tract, the number and severity of acute
exacerbations and the usage of antibiotics. These outcomes were
not always statistically useful.
Corticosteroids were administered at a similar rate in both active
and placebo groups. Antibiotics were prescribed in both arms of
the trial according to standard respiratory medicine clinical crite-
ria at the time of the respective trials. Such criteria included in-
crease in volume and purulence of sputum, usually with increased
breathlessness and sometimes fever.
Clancy 1985 was carried out and published by Clancy in 1985 and
1987 and is the oldest trial relevant to this review. It is a double-
blind, placebo-controlled RCT conducted in New South Wales
(Australia) over a period of three months in the winter of 1983.
The mean age in the treatment group was 65.5 years and in the
placebo group it was 64.7 years. Its focus was the immunogenic-
ity of the H. influenzae oral vaccine and the clinical impact on
patients with airways damaged by COPD who suffer recurrent
episodes of acute bronchitis. Fifty patients with COPD (not tak-
ing corticosteroids or immunosuppressants) were recruited from
the chest clinic of the Royal Newcastle Hospital and were given
a three-day course of tablets (two daily) at 0, 28 and 56 days.
Placebo and non-typeable Haemophilus influenzae (NTHi) vac-
cine were both enteric-coated. Clancy 1985 utilised two placebo
arms in their trial; the first group was given enteric-coated glu-
cose tablets and the second was given sodium tauroglycocholate.
We have used the results from the first placebo group as this is a
standard, widely used placebo, rather than the sodium taurogly-
cocholate group as this placebo may have contributed some thera-
peutic effect. Participants were assessed by a chest physician, lung
function (spirometry), throat cultures and saliva samples collected
at baseline, 28, 56 and 84 days. The characteristics of participants
entered into the trial demonstrated a very representative popula-
tion; older adults (mean age 65 years), majority male (M:F 4.5:
1), majority smokers (86%). H. influenzae was isolated from 69%
of sputum samples collected during acute bronchitis episodes in
this population. Clancy 1985 concluded that the NTHi vaccine
resulted in over 90% protection against acute exacerbations com-
pared to the placebo group. This was not still the case at follow-up
a year later, at which point there was also no significant reduction
in incidence ofH. influenzae carriage. That is, no clear correlation
between clinical protection from acute exacerbations and either
carriage of H. influenzae or the level of antibody to H. influenzae
antigen in saliva was evident. It was also noted that the protection
provided by the vaccine did not extend to the subsequent winter,
which is consistent with the knowledge that mucosal immunity is
less durable than systemic immunity.
Clancy 1990 was a double-blind RCT trial conducted in Australia
over a six-month period. There were a total of 37 participants with
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each group having similar baseline characteristics. This study had
a population with a mean age of 65.5 +/- 2.9 and they were re-
cruited from a chest clinic in Newcastle. Episodes were defined by
an increase in purulence and volume of sputum with associated
fever, cough, shortness of breath and antibiotic therapy. Each par-
ticipant was assessed by a chest physician, completed a respiratory
questionnaire (ATS OLD 78), and had sputum and mixed saliva
samples taken and lung function via spirometry. Each group re-
ceived three courses of oral tablets for the three consecutive days
at 0, 28, 56 days. One group received the active preparation con-
tainingH. influenzae vaccine while the other group received a glu-
cose-containing placebo preparation. There was a significant re-
duction in the number of episodes of acute wheezy bronchitis in
the treated group with a P value of 0.02. There was a significant re-
duction (41%) in the total number of acute infections in the treat-
ment group compared to placebo group but no significant change
when acute infections were considered in an individual from either
group. This study had other modes of measuring severity, such as
the number of participants reporting infections and the number
of infections prescribed antibiotics, and all the results supported
the treatment group. There was no significant difference noted in
the side effect profile in either group.
Clancy 2013 was a double-blind, placebo-controlled, prospective
study conducted for nine months over the Australian winter of
2011. Participants included 320 moderate-severe COPD partic-
ipants with FEV1 < 60%, requiring oral systemic corticosteroid
therapy or admission into hospital and they were recruited from
21 sites across Australia; the mean age of participants in the treat-
ment arm was 71.2 years and in the placebo arm was 67.9 years.
Patients in the intervention group were given twoHI-164 oral vac-
cine enteric-coated tablets per day that each contained 45 mg of
the formalin-inactivated NTHi (HI-164) active vaccine, with the
placebo group receiving a glucose substitute. Its outcomes assessed
the number of exacerbations (according to the St George’s Respi-
ratory Questionnaire), carriage levels (from cultured sputum sam-
ples), hospitalisations and antibiotic/steroid prescriptions (based
on medical records). The aim of this study was to extend the
database from earlier and smaller studies showing that maximum
protection occurred in those with most severe disease, with the
most sensitive indicator being a reduction in exacerbations requir-
ing corticosteroid therapy and/or hospital admission. This current
study provides evidence that the age-related vaccine benefits in
COPD noted with parenteral vaccines apply also to oral vaccines
that enhance mucosal immunity within the bronchus. The results
were only minutely significant in circumstances of low exposure
to NTHi and only amongst a subgroup of younger participants
(aged under 65), given more responsive immune systems and less
established airway disease. The results were otherwise not signifi-
cant for those older than 65 years of age.
Lehmann 1991 was a prospective, double-blind RCT, conducted
through the Pneumonia Research Programme in Papua New
Guinea. As a result, the demographic characteristics are signifi-
cantly different to those found in high-income communities. Po-
tential participants were identified by nomination from town res-
idents and villagers and were then followed up by a standard ques-
tionnaire, which identified people suffering from chronic lung dis-
ease. Participants who matched the eligibility criteria were exam-
ined with lung function tests and spirometry at time of entry into
the trial. Randomisation and blinding of medication and placebo
was done by the pharmacy department at the Royal Newcastle
Hospital, New SouthWales; the placebo and active vaccine looked
identical and the randomisation code was held by Auspharm In-
ternational Ltd until the completion of the trial. Both groups were
similar at baseline following allocation. Administration of med-
ication was overseen by doctors and nurses to maintain compli-
ance in the 12-month follow-up period. Patients lost to follow-
up included eight in the vaccine group and three in the placebo
group, with three deaths in the vaccine group and one death in the
placebo group. The trial does not mention any intention-to-treat
(ITT) analysis for these patients, rather stating “permanent exit
from the study were excluded from the calculation”, potentially
creating attrition bias. The trial concludes that for the popula-
tion of the highlands of Papua New Guinea the vaccine protected
against episodes of acute bronchitis, but not against more severe
forms of acute lower respiratory tract infection. A limitation of the
study was the need for a larger population group to ensure greater
statistical power to help determine the extent of protection oral
H. influenzae vaccine could provide.
Tandon 1991 was a double-blinded RCT, conducted in 1988 at
the repatriation hospital inWestern Australia. This study recruited
64 participants with chronic bronchitis and a history of recurrent
respiratory tract infections in order to find out whether oral NTHi
immunisation is effective in this participant group. Participants
were divided randomly into placebo (mean age 71.1 years) and vac-
cine (mean age 73.1 years) groups. All the participants followed the
same treatment regime consisting of three courses of the tablets on
days 0, 28 and 56. Study outcomes were acute infective episodes,
number of antibiotic prescriptions and colonisation with H. in-
fluenzae, monitored through the following strategies: primary care
physician for diagnosing acute infective episodes, sputum sample,
visual analogue scale (VAS). For all of these variables, better out-
comes were demonstrated in the vaccine group. Previous studies
have demonstrated that H. influenzae was the main constituent
in bacterial colonisation of the bronchus and therefore vaccinat-
ing against it would reduce the incidence of acute exacerbations,
which is consistent with the results of this study.
Tandon 2010 was amulticentre, double-blind, placebo-controlled
trial conducted at four sites around Australia. The study tested
the efficacy of HI-164OV in reducing the number and severity of
acute exacerbations in participants with severe COPD.Acute exac-
erbations were defined by an increase in volume and purulence of
sputum. Each participant took the same regime (two tablets daily
for three consecutive days) with courses repeated at day 28 and
56. All tablets were identical-looking, enteric-coated capsules that
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contained either vaccine (N =18) or placebo (N =20). Participants
were followed up every four weeks via a respiratory questionnaire,
sputum and nasopharyngeal swabs were collected to monitor bac-
terial colonisation and blood samples were collected to monitor
antibodies. The primary variables were the number and duration
of exacerbations and the number of antibiotic courses prescribed.
Baseline demographic characteristics, such as mean age (vaccine
69.5, placebo 67.5) were very similar, demonstrating effective ran-
domisation. However the exact method of randomisation was not
disclosed. Four of the six authors of this study disclosed that they
had received funding fromHunter Immunology Limited. The au-
thors concluded that the vaccine was safe and had a significant
efficacy in participants with severe COPD. Benefits were noted
with respect to a reduction in the severity of episodes (duration of
episodes; 14.3 vaccine group and 22.7 placebo, P value < 0.01),
which required less antibiotic therapy (event rate; 0.83 vaccine
and 1.15 placebo, P value < 0.05) and fewer admissions to hos-
pital (three in the vaccine group compared to 12 in the placebo
group, P value < 0.05). However, a reduction in the incidence of
episodes did not reach significance possibly because the study was
significantly underpowered.
Excluded studies
We excluded one study because it did not meet our inclusion crite-
ria (Clancy 2010). As noted in Characteristics of excluded studies,
the participant population included smokers who did not have
formally diagnosed COPD or chronic bronchitis and outcome
measures were limited to physiological markers that did not in-
clude the clinical outcomes defined in this review’s protocol.
Three studies are cited only in trial registries and pending
formal publication of the raw trial data by the investigators
(ACTRN12606000074594 2013; ACTRN12606000076572
2013; ACTRN12610000916044 2013). The main features of
these unpublished trials can be found in Characteristics of studies
awaiting classification. These trials have potential to be incorpo-
rated into future updates of this review.
Risk of bias in included studies
A summary of the ’Risk of bias’ assessment is detailed in the
Characteristics of included studies table.
Allocation
The random sequence generation in the studies was generally de-
termined to be poor, with 50% of the studies graded as either
high or unclear risk (Clancy 1985; Clancy 2013; Tandon 2010),
because they did not provide any information regarding the ran-
dom sequence generation and subsequent allocation process. We
considered the remaining studies to have a low risk of bias given
that there were reports that a third party conducted randomisation
and the allocation codes were kept confidential until the end of
the trial (Clancy 1990; Lehmann 1991; Tandon 1991).
The allocation concealment in the selected studies was generally
poor, with 67% of the studies categorised as either unclear or high
risk of bias (Clancy 1985; Clancy 1990; Clancy 2013; Tandon
2010). Only two studies demonstrated a low risk of bias, where the
handling and distribution of the treatment packages was carried
out independently by the pharmacist who employed an appro-
priate randomisation chart and safely kept the package trial code
associated with the patient (Lehmann 1991; Tandon 1991).
Blinding
Suitable blinding was performed in all studies, except for one,
which we deemed to be at high risk as it did not blind the com-
mercially available polybacterial tablets (Clancy 1990). For this
reason, the study was subsequently conducted as a single-blinded
trial (participants blinded). All of the studies reported using iden-
tical enteric-coated tablets for both intervention and placebo arms
of the trial.
Incomplete outcome data
Five of the six included studies accounted for and provided suffi-
cient information regarding the follow-up of patients that dropped
out of the trials (Clancy 1985; Clancy 1990; Clancy 2013; Tandon
1991; Tandon 2010). Lehmann 1991 made no mention of in-
tention-to-treat analysis and reported a substantial loss to follow-
up (eight participants from the vaccine group and three from the
placebo group), especially considering the small group size.
Selective reporting
We found no selective reporting in any of the studies.
Other potential sources of bias
We identified no other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
1. Incidence of acute exacerbations of chronic bronchitis or
chronic obstructive pulmonary disease (COPD)
Six trials evaluating 557 patients assessed the effectiveness of non-
typeable Haemophilus influenzae (NTHi) oral vaccination on the
frequency of acute exacerbations in patients with advanced lung
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disease (Figure 2; Table 1). Themeta-analysis concluded that there
was a small, non-significant 2.048% decrease in exacerbations in
the vaccinated group when compared to the placebo group (risk
ratio (RR) 0.97, 95% confidence interval (CI) 0.84 to 1.12, P
value = 0.68) (Analysis 1.1).
Figure 2. Forest plot of comparison: 1 Primary outcomes, outcome: 1.1 Exacerbations (number of
exacerbations/person/year).Refer to for Overall rate estimates of acute exacerbations across included studies.
Despite all trials having almost identical primary objectives, there
was a considerable discrepancy in the manner in which the pri-
mary outcomeswere reported. For example, Clancy 1985 reported
overall number of infections, whereas Tandon 2010 reported the
number of infections per participant. In order to allowmeaningful
comparisons between studies we converted all data into a rate of
exacerbations (number of exacerbations per participant per year).
Of the six studies incorporated into the review only one demon-
strated an effect that favoured the vaccination group (Clancy
1985). Clancy 1985 is a small trial, which enrolled 33 partici-
pants. The data showed a very significant positive effect in favour
of the vaccine group, only recording one event compared to the
13 in the placebo group, which was statistically significant (RR
0.07, 95% CI 0.01 to 0.55) despite the very large CI. However,
subgroup analysis demonstrated that removing this study from the
pool had no bearing on the overall meta-analysis outcome as its
small population meant this study’s weighting was very small.
Five studies, with a total of 504 participants, did not show a sig-
nificant increase in the number of exacerbations (Clancy 1990;
Clancy 2013; Lehmann 1991; Tandon 1991; Tandon 2010). As a
result, their combined contribution to this meta-analysis weight-
ing was 99.5%.
Clancy 2013 is the largest trial, comprising 320 patients and re-
ceiving over 70% of the meta-analysis weighting. It shows a non-
significant 8% increase in the number of exacerbations in the
placebo group (RR 1.08, 95% CI 0.91 to 1.29). Clancy 2013 re-
ports 249 events in the vaccine group compared with 270 in the
placebo group.
There is a moderate degree of heterogeneity in this meta-analysis
(I2 statistic = 57%, P value = 0.04). The study that contributes
most to this effect is the Clancy 1985 trial. Removal of Clancy
1985 dramatically reduces the heterogeneity (I2 statistic = 24%
and the P value = 0.26).
2. Mortality
Mortality was not formally assessed as an outcome in any of the tri-
als.However, five trials reported deaths of trial participants (Clancy
1985; Clancy 2013; Lehmann 1991; Tandon 1991; Tandon 2010)
(Figure 3). Of these deaths, none were attributed to the vaccine
andmost were considered the natural endpoint of their respiratory
disease or other unrelated chronic disease. There was a greater in-
cidence of mortality in the placebo group. However, this result was
not statistically significant (odds ratio (OR) 1.62, P value = 0.31),
with a low amount of heterogeneity between results (I2 statistic =
9%, P value = 0.36) (Analysis 1.2).
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Figure 3. Forest plot of comparison: 1 Primary outcomes, outcome: 1.2 Mortality (deaths during trial
period).
Secondary outcomes
1. Carriage level of NTHi in the respiratory tract
Analysis of carriage levels ofH. influenzae in patients with chronic
bronchitis was attempted in all six RCTs. No meta-analysis could
be performed as there were amyriad of different techniques used to
measure carriage levels objectively (throat swabs, sputum samples
and culture) and carriage rates weremeasured at different intervals.
Of all the trials, three failed to find a significant difference between
carriage levels (Clancy 1985; Clancy 1990; Tandon 1991). Two
studies showed a significant decrease in carriage rates in the vaccine
group (Lehmann 1991; Tandon 2010). In one study carriage levels
were measured but sputum samples could only be obtained at
36% of planned visits, of which 11% grew a respiratory pathogen;
these numbers were too small to determine any significant effect
following vaccination (Clancy 2013).
Lehmann 1991 showed that during acute exacerbations the mean
concentrations of H. influenzae carriage levels were higher in the
vaccine group (8.91 x 106 colony-forming units (cfu)) when com-
pared against the placebo (1.55 x 106 cfu). However, this only
equated to a 5% difference between the vaccinated and placebo
arms when counting individual specimens, whereby 91% of the
vaccinated and 86% of the placebo collected specimens success-
fully grew H. influenzae colonisations during the trial period.
Tandon 2010 demonstrated that there was a significant (P value <
0.05) two-fold difference between the placebo and active arms in
overall positive cultures (65 positive cultures in the placebo group
compared to 33 in the vaccine group). However, the percentage of
validated sputum sampleswas 50%and48%for placebo and active
groups, respectively. H. influenzae only accounted for 51% and
33% of positive cultures in the placebo group and the vaccinated
group, respectively.
There was a trend for studies to report a transient decline in H.
influenzae carriage levels. However, this had always returned to
baseline by the end of the study time frame. Tandon 1991 noted
a transient drop in carriage levels to 12% at 14 weeks in the active
group, which then reverted back to 25% at 24 weeks. This is a 4%
drop over 24 weeks. The placebo group noted a small 2% drop
over the 24-week study period. Furthermore, in Clancy 1985 H.
influenzaewas isolated from throat swabs from 70% of the placebo
group compared with 53% of the vaccination group at the end of
a four-week period. Carriage rates at 12 weeks declined to 50% in
the placebo group and 23% in the vaccine group.
2. Numbers of prescriptions for antibiotics and
corticosteroids in the trial and follow-up periods (including
hospital admissions) as an indication of severity of acute
exacerbations
Four studies, evaluating 462 patients, assessed the effect of NTHi
oral vaccination on the number of antibiotic prescriptions in
patients with chronic bronchitis (Clancy 1990; Clancy 2013;
Tandon 1991; Tandon 2010) (Figure 4; Table 2).
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Figure 4. Forest plot of comparison: 2 Secondary outcomes, outcome: 2.1 Prescriptions (number of
courses/person/year).Refer to for Overall rate estimates of antibiotic prescriptions across included studies.
There were considerable discrepancies amongst studies in the way
antibiotic prescriptions were objectively measured. We attempted
to convert the reported data into a rate (number of courses/person/
year) so an objective comparison could be achieved. However, this
was not possible with data from the Clancy 2013 trial, which only
reported mean antibiotic use in days unlike the other studies. As
a result, only three studies could be pooled in meta-analysis. Two
studies did not report any information on antibiotic usage in this
population (Clancy 1985; Lehmann 1991).
The three studies in the meta-analysis included 143 patients
(Clancy 1990; Tandon 1991; Tandon 2010). Two of these studies
produced data that favoured the vaccination group (Tandon 1991;
Tandon 2010), whereas the Clancy 1990 data did not reach sig-
nificance. The overall effect was a statistically non-significant 81%
increase in use of antibiotic courses per person in the placebo group
when compared against the vaccinated group (RR 1.81, 95% CI
1.35 to 2.44, P value = 0.61; with a RR > 1.0 indicating greater
use of antibiotic usage in the placebo group) (Analysis 2.1). The
majority of the weighting could be attributed to Tandon 1991 and
Tandon 2010; 64.9% and 31.1%, respectively, and both favoured
the vaccination group.
Tandon 1991 showed a significant decrease in antibiotic prescrip-
tions (45 in the active group and 79 in the placebo group). Tandon
2010 showed a significant 56% reduction in the number of pre-
scribed antibiotics following active treatment (P value < 0.05). The
Clancy 1990 trial reports a reduction in the number of antibiotics
in the active group compared to placebo, but this failed to reach
statistical significance.
TheClancy 2013 trial is by far the largest study in this review (three
times the combined size of the other three trials), contributing 320
of the 462 patients. Clancy reported that there was no significant
difference between the two groups in terms of antibiotic usage
(active group 13.5 days per episode with a range of 0 to 289;
placebo group 14 days per episode with a range of 1 to 122). Given
the wide and varied protocols for antibiotic administration it was
impossible to translate this into course/person/year as with the
other trials.
Corticosteroid prescriptions were not strictly studied as an out-
come in the studies, and thus we did not meta-analyse these;
nonetheless, usage was noted in participants in at least two studies
(Clancy 2013; Tandon 2010), and we have considered their indi-
cations and study findings for their use in the Summary of main
results.
Hospitalisation data amongst the studies were limited, with only
two studies reporting hospitalisations of their participants (Clancy
2013; Tandon 2010), with significant heterogeneity noted (I2 >
84%). The results demonstrate no significantly increased likeli-
hood of being hospitalised in either the vaccinated or placebo
group (OR 0.96, 95% CI 0.13 to 7.04, P value = 0.97) (Analysis
2.2; Figure 5).
Figure 5. Forest plot of comparison: 2 Secondary Outcomes, outcome: 2.2 Hospital admissions (number of
patients hospitalised during trial period).
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3. Any associated adverse side effects from the NTHi
vaccination, measurable from symptomology and
participant reports
All studies, except Clancy 1985, reported adverse events, although
none of the trials studied this as an outcome. In total, between
the other studies, 142 adverse events were reported; of these, 72
occurred in the active group and 68 occurred in the placebo group
(Analysis 2.3; Figure 6; Table 3). Reported adverse effects were
largely gastrointestinal in nature, although others commonly re-
ported increased dyspnoea or general malaise; none of these were
directly evidenced to be attributable to the oral vaccine.
Figure 6. Forest plot of comparison: 2 Secondary outcomes, outcome: 2.3 Adverse events (number of
adverse events/person/year).Refer to for Overall rate estimates of adverse events across included studies.
Clancy 2013 reported that adverse event rates were similar in both
groups (placebo group 33.5% compared with 38.5% in the vac-
cinated group), although the actual number of events was not
provided in the original publication. Further data additionally re-
quested from the study authors show that one participant in the
active group had an adverse event compared with three in the
placebo group.
4. Quality of life
Only two studies reported quality of life measurements, however
they used different assessment scales and are not comparable; we
therefore did notmeta-analyse them (Clancy 2013;Tandon 1991).
Tandon 1991 reported a global assessment for general well-being
using a visual analogue scale (VAS). It reports at 24 weeks amedian
score of 5.0 in the vaccine group compared to 2.5 in the placebo
group (P value = 0.09). Clancy 2013 measured quality of life using
the St George’s Respiratory Questionnaire for COPD (SGRQ-C)
for those under 65 years old. They reported a significant difference
in symptom scores in favour of the vaccine group at three months
(P value = 0.02) and six months (P value = 0.01). Data were not
provided for older age groups.
D I S C U S S I O N
Summary of main results
Incidence of acute exacerbations of chronic bronchitis
or chronic obstructive pulmonary disease (COPD)
In this review we evaluated the effectiveness of a non-typeable
Haemophilus influenzae (NTHi) oral vaccination in reducing acute
exacerbations in patients with chronic bronchitis/chronic obstruc-
tive pulmonary disease (COPD). The results indicate that the vac-
cination has no significant impact in reducing the number of ex-
acerbations. Only one study was able to demonstrate a statistically
significant effect, which favoured vaccination (Clancy 1985). This
was the smallest study and contributed significant heterogeneity
to the meta-analysis. When we removed Clancy 1985 from the
meta-analysis, we found no significant difference for the primary
outcome. All other studies showed no significant treatment effect.
Among the studies included in the review, there are considerable
differences in the methodology and intervals at which measure-
ments were recorded. The main outcome (acute exacerbations)
was measured differently across the six studies, providing a chal-
lenge for comparison. For example, Clancy 1985 records results as
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a proportion whereas Lehmann 1991 utilises rates. There are also
notable discrepancies in the study time periods, with Clancy 1985
reporting data at three months and Clancy 1990 providing data
up to six months. Data recorded at nine to 12 months could only
be elicited from two trials. As a result we converted all data into
rates so that studies could be objectively compared, irrespective of
their varying follow-up protocols.
Other differences amongst the trials included variation in popula-
tion (Lehmann 1991 was conducted in Papua New Guinea), the
use of subjective measurements such as respiratory questionnaires
to measure exacerbations and seasonal variations. These may have
contributed to the marked heterogeneity (I2 statistic = 57%; P
value = 0.04) identified in the meta-analysis.
Only one study was large enough to be able to conduct subgroup
analysis stratified by age (Clancy 2013). A subgroup analysis ex-
cluding all patients greater than 65 years of age concluded that
the mean number of exacerbations was significantly higher in the
placebo group (56) when compared to the vaccinated group (34)
(P value = 0.0015). There was also a statistically significant differ-
ence in the days to first exacerbation (87 days in the placebo group
compared to 111 days in the vaccine group). Although the data
are limited at this stage, these results suggest the use of the NTHi
vaccination in a younger population, especially considering that
there was no difference in mortality or adverse events in these two
groups. The apparently greater efficacy of the vaccine seen in those
less than 65 years old may be a reflection of a less severe burden
of disease; younger patients generally have a shorter smoking his-
tory, fewer exacerbations and fewer co-morbidities. Further stud-
ies need to be conducted in younger patients and considering the
varying severity of COPD to identify whether there is a significant
treatment effect in this population.
Mortality
We foundmortality rates overall to be higher in the placebo group.
However, these results were not statistically significant and are
unconvincing. There was no apparent association with treatment
effect and it is unclear whether the administration of the NTHi
vaccine contributed to mortality.
Other patient factors were suggested in some trials to contribute to
mortality, such as long-standing cirrhosis or a ruptured aneurysm
reported in Tandon 1991 and Lehmann 1991. These co-morbidi-
ties would have a significant effect on the mortality outcome given
the small participant numbers.
Two trials reported the primary cause of death as a terminal respi-
ratory infection (Lehmann 1991; Tandon 1991), with other stud-
ies reporting cause of death to be non-respiratory. Whilst it is un-
derstood that the most common cause of death in COPD patients
is respiratory failure, it was not clearly demonstrated in this meta-
analyses, which was likely due to inconsistent and insufficient re-
porting in the studies.
Carriage level of NTHi in the respiratory tract
All six trialsmeasured sputum carriage levels ofH. influenzae; these
were obtained routinely and during acute exacerbations, although
the methods of reporting and intervals at which routine samples
were taken differed. This limited the extent to which these results
could be compared.
A significant difference in the carriage rates was not consistently
found between the placebo and vaccine groups in every trial. No
significant difference over time in routine carriage rates was found
between the groups in Clancy 1985, Lehmann 1991 and Tandon
1991. The largest of the studies obtained samples at only 36%
of visits and of these, a respiratory pathogen was isolated in only
11% (Clancy 2013). The sputum carriage levels were too small to
determine any significant effect following vaccination.
In the majority of trials, H. influenzae was noted to play a promi-
nent role during infective exacerbations. In Clancy 1985, H. in-
fluenzae was isolated from 69% of sputum samples collected dur-
ing acute exacerbations; and from 33% and 44% in the placebo
and vaccine groups respectively in Clancy 1990 (this difference
was not significant). Lehmann 1991 and Tandon 2010 did not
discuss the bacterial carriage specifically during acute exacerba-
tions. It is notable that Tandon 1991 found that the numbers of
acute infective exacerbations were higher (P value = 0.011) in par-
ticipants in the vaccine group from whose sputum H. influenzae
was isolated either before or during an acute episode.
Clancy 2013 noted that of the sputum samples that grew a respi-
ratory pathogen, H. influenzae played a role, but not a prominent
one, accounting for only 6%. 6.2% grew Streptococcus pneumo-
niae, 7.5% Moraxella catarrhalis and 6.0% Pseudomonas aerugi-
nosa. Clancy 1990 noted that during the six-month trial, the pro-
portion ofH. parainfluenzae infectionswas between 57%and 89%
greater than the proportion of H. influenzae infections during the
same time period across both groups. This poses the question of
the clinical impact of treating H. influenzae as prophylaxis, as the
background carriage rates may reflect the rates in acute exacerba-
tion. Also, many of the studies did not mention whether other
pathogens were also found in the sputum samples that isolated
H. influenzae; how many acute exacerbations are due to multiple
organisms?
The population studied in the PapuaNewGuinea study (Lehmann
1991) raises concerns about the potential applicability of the re-
sults to the COPD patient in a high-income country. Asymp-
tomatic background carriage rates were high; 57% of routine spu-
tum samples isolated H. influenzae (37% isolated S. pneumoniae
and 11% demonstrated H. parainfluenzae). There were also some
significant methodological problems, with 53 out of 362 samples
having to be excluded due to betel nut consumption or epithelial
contamination.
Numbers of prescriptions for antibiotics and
corticosteroids in the trial
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Antibiotics were prescribed in four out of the six clinical trials
(Clancy 1990; Clancy 2013; Tandon 1991; Tandon 2010), but
this was not necessarily an effective outcome measure that cor-
related with disease progression or severity. Given the high vari-
ability and lack of consistency concerning antibiotic course ad-
ministration and measurements, a truly uniform assessment and
comparison could not be performed amongst the trials.Whilst the
three studies pooled for quantitative analysis appear to indicate
slightly more prescriptions having been issued to participants in
the placebo group (odds ratio (OR) 1.81, P value < 0.05) (Clancy
1990; Tandon 1991; Tandon 2010), this conclusion remains un-
convincing. There was also no reported follow-up regarding what
effect antibiotics had on patients (that is, for instance, if there was
resolution of symptoms or reduction in carriage levels).
The application of current therapeutic guidelines in the trials was
similarly questionable, with the intentions and protocols for pre-
scribing antibiotics largely unclear and not reported in their meth-
ods. It is understood that at least half of patients with chronic
bronchitis and COPD are persistently colonised with H. influen-
zae, S. pneumonia orM. catarrhalis (Lehmann 1991), hence a pos-
itive sputum culture that is not necessarily indicative of an acute
infection and subsequent antibiotic prescription (in Tandon 2010,
48% in the vaccinated group and 50% in the placebo group had a
validated positive sputum culture). Normally in exacerbations of
COPD, sputum cultures would only be done if there was a failure
of response to treatment or if the patient had repeated bacterial ex-
acerbations within several months. Nonetheless, these organisms
may be responsible for more severe exacerbations, in which antibi-
otics have been shown to be of benefit. The aim of treatment with
antibiotics in acute exacerbations should be to alleviate symptoms
and reduce the volume of sputum rather than total elimination of
colonising organisms.
None of the trials specified the class of antibiotic therapy used, nor
did they explore sensitivities. This is important given that currently
only amoxicillin and doxycycline regimes have been shown to be
superior over other antibiotic classes, such as macrolides, which
fail to suppress H. influenzae (Longo 2011).
Corticosteroid use was measured as an outcome in two trials
(Clancy 2013; Tandon 2010). Clancy 2013 reported a median
duration of five treatment days (minimum 0, maximum 313) in
the vaccine group and 10 days (minimum 0, maximum 306) in
the placebo group. Tandon 2010 reported a 56% reduction in
the proportion with acute exacerbations with corticosteroid treat-
ment; for all episodes the proportion with recurrent exacerbations
was less than in the treated group (0.33 per participant compared
with 0.55 per participant, 40% reduction).
Even though two studies reported the use of corticosteroids for
the treatment of acute exacerbations, this does not preclude par-
ticipants from receiving corticosteroids prior to and during the
studies. Many of the participants were admitted to hospital during
the study period and were likely to have received a short course of
systemic corticosteroids (in Clancy 2013 and Tandon 2010, a total
of 83 participants in the vaccinated groups and 56 in the placebo
groups). Short (not extended) courses of oral prednis(ol)one or
intravenous hydrocortisone have been shown to shorten the du-
ration of hospital admission and hasten return to previous lung
function and stable symptom control and are routinely used for
severe exacerbations of COPD (Longo 2011).
Hospitalisations
Two studies reported hospitalisations (Clancy 2013; Tandon
2010). There are limited data and information in the studies
regarding participant hospitalisations; Analysis 2.2 demonstrates
that those vaccinated were no more unlikely to be hospitalised
(OR 0.96, 95% confidence interval (CI) 0.13 to 7.04, P value =
0.01) based on a simple count of the number of participants hav-
ing been hospitalised during the respective study period. Further
data parameters, such as length of hospital stay and intensive care
versus general ward admission, would have been necessary for a
more complete analysis.
In the Tandon 2010 study, admissions to hospital were very high in
the placebo group, with 11 admissions compared to one admission
in the vaccination group. This demonstrates that those receiving
the NTHi vaccine had the chance of hospital admission reduced
by 90% (P value = 0.05). A similar outcome was noted in Clancy
2013, showing a 50% reduction in hospital admissions following
an acute exacerbation in the vaccine group (P value = 0.047).
Any associated adverse side effects from the NTHi
vaccination, measurable from symptomology and
participant reports
There was no clear definition of what constituted an adverse effect
and therefore no consistency between the studies’ reporting of ad-
verse events. For example, Tandon 1991 includes increase of dys-
pnoea and cough as an adverse event, while Clancy 2013 reports
mortality as a severe adverse event. Methods used for monitoring
adverse events were not reported in any of the trials. Thus there is
potentially an under-reporting of less severe side effects. No clear
comparisons or conclusions could be reached regarding any asso-
ciation between adverse effects and therapeutic effect. The adverse
effects presented in the trials may well have been attributable to
the significant comorbidity of the patient rather than to the vac-
cine. To discern whether these symptoms or adverse effects were
true side effects of the vaccine or whether they were sequelae of
the patient’s disease process was not possible in this review as in-
sufficient primary study data were available.
Quality of life
Only two studies reported quality of life (QoL) measures (Clancy
2013; Tandon 1991), and these trials used different measurement
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tools, limiting comparisons that could be made between the re-
sults. It is also notable that, by nature, the measurement of qual-
ity of life is subjective and difficult to quantify; neither studies
provided further data and information regarding which aspect of
QoL was most improved. Nonetheless, both trials report at least a
two-point improvement in patient QoL in the vaccinated groups
versus placebo. Improvement in QoL was based on overall clinical
condition assessed at the start of the trial and at set points during
the trial. These intervals were slightly different between the two
trials, with Tandon 1991 measuring at six months and Clancy
2013 measuring at three and six months. Clancy 2013 did not
provide data on QoL for participants over 65 years of age.
Overall completeness and applicability of
evidence
Although the number and size of the studies were low, all the tri-
als included participants with established chronic obstructive pul-
monary disease (COPD) or chronic bronchitis. Clancy 2013 was
the only study with sufficient sample size to conduct subgroup
analyses that assessed the effects of the vaccine in patients less
than 65 years of age. The majority of studies (with the exception
of Lehmann 1991, which was conducted in Papua New Guinea)
were conducted in an Australian population. However, trial length
and follow-up periods varied from three to 12 months among the
trials. The majority of the studies administered the HI-164 oral
vaccine enteric-coated tablets (two per day), which each contained
45 mg active substance of formalin-inactivated NTHi, which was
compared with enteric-coated placebo tablets (with the exception
of Clancy 1985, which used a sodium tauroglycocholate substi-
tute for the placebo). All studies had comparable objectives that
assessed the vaccine’s effect on acute COPD exacerbations.
We consider the results of this review to be applicable to patients
with established COPD.
Quality of the evidence
Overall, the methodological quality of the trials was acceptable
with most reporting methods of random sequence generation and
allocation concealment sufficiently to assess them as adequate. The
greatest limitation of the included studies is that of the six trials one
is by far the largest in terms of included population. The smaller
studies were underpowered and evenwhen pooling the five smaller
studies, their weighting is inferior to that of the one larger trial
(Clancy 2013).
The assessment of primary outcomes of acute exacerbations was
carried out through respiratory questionnaires, which are subjec-
tive, instead of using objective measures such as spirometry. Other
secondary outcomes, such as H. influenzae colonisation and an-
tibiotic use, are more objective measurements but may be difficult
to measure. Studies had low rates of losses to follow-up and attri-
tion rates were low and equal in both arms of the trials.
There is a moderate degree of heterogeneity to be found in this
meta-analysis, specifically in the outcome that measures the num-
ber of acute exacerbations of COPD (I2 statistic = 57%, P value
= 0.04). Clancy 1985 appears to contribute most to the hetero-
geneity; its exclusion from the analysis dramatically reduces het-
erogeneity (I2 statistic = 24% and P value = 0.26) and can likely be
attributed to the study’s reported result of only one exacerbation in
the vaccinated group. Nonetheless, the exclusion of Clancy 1985
from the meta-analysis did not appear to have a significant impact
on the overall result, given the small study size of approximately
30 patients and the robustness of the data sourced from the re-
maining studies.
Potential biases in the review process
Two review authors conducted all data selection and extraction
independently, with a third author acting as an arbiter, in order
to minimise the risk of error and bias. One of the authors (AC)
was involved as an investigator in four of the six included trials
(Clancy 1985; Clancy 1990; Clancy 2013; Lehmann 1991), but
not involved in the data extraction and analysis in the review in
order to reduce interpretation bias.
It is possible that despite extensive searching we may have missed a
trial. However, this is very unlikely as one of the review authors is a
world-renowned expert in the field and has consulted his extensive
network to search for additional unpublished data. Therefore, we
think that we have captured all available evidence in this review.
Agreements and disagreements with other
studies or reviews
This is an update of a previously withdrawn Cochrane review of
the same title (Foxwell 2006). The authors of the previous review
concluded that the vaccine was efficacious in reducing 20% to
30% of acute exacerbations in COPD patients and supported its
use clinically. They also concluded that there was a need for larger
clinical trials to assess longer-term prognosis. Since publication of
the previous review a new trial with a substantially larger popu-
lation has been published (Clancy 2013), and we have been able
to include this in our updated meta-analysis. As a result of the
inclusion of this large trial the validity of the review has increased
and the conclusions have changed substantially.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
This review analysed six trials of monobacterial whole, killed, non-
typeable H. influenzae (NTHi) vaccine in patients experiencing
recurrent acute exacerbations of chronic obstructive pulmonary
disease (COPD). Our results do not support the use of the vaccine
in reducing the number and severity of exacerbations.
Implications for research
Future trials should address the long-term effects of theNTHi oral
vaccine. It would be useful to assess further both the outcomes at
12 months and two years following the initial vaccination, along-
side gathering data on mortality, age and other contributing fac-
tors. It may also be useful to assess the effect of regular (seasonal)
vaccination over a longer period of time. Careful standardisation
of the measurement protocols is necessary for consistent analyses
for outcomes in the areas of number of acute infective exacer-
bations, severity of exacerbations, carriage levels of H. influenzae
and associated microbiology, hospital admissions and prescription
of antibiotics and corticosteroids. As polymerase chain reaction
(PCR) is becoming more widely used in the diagnosis of infec-
tion, it may have a role in future research given the limitations
of cultures, especially for micro-organisms such as H. influenzae,
which are difficult to serotype. Future studies should more clearly
assess and consider the use of antibiotics and steroids in COPD
patients with H. influenzae, as these are common therapies that
have a significant influence on mortality and morbidity, alongside
bronchodilators, oxygen therapy and ventilatory support.
The concept that COPD is a chronic condition with a peak in-
cidence of diagnosis in patients aged between 50 and 60 years of
age means that patients involved already have well-established air-
way disease. Whilst the inclusion criteria for this review and tri-
als concerning this vaccine specified those already diagnosed with
COPD, it is equally important to assess the potential benefits of
vaccinating patients with a pre-disposition to developing COPD
(for example, younger populations of heavy smokers withmild air-
way disease that have not reached a chronic condition yet). Future
research should therefore also be directed at assessing the effects
of H. influenzae oral vaccination in high-risk populations not yet
diagnosed with COPD, as a means of establishing the prophylac-
tic capabilities of such a vaccine.
The projected annual cost of COPD in the United States will in-
crease fromUSD 176.8 to USD 832.9 billion in the next 20 years,
with the majority of direct costs attributed to acute exacerbations
(Lee 2006). As COPD is a non-curable disease, any cost-effective
intervention to prevent exacerbations would be worth further re-
search, considering the rising global prevalence and financial bur-
den of treatment on the health system.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Clancy 1985
Methods Double-blind, placebo-controlled, prospective RCT over a 3-month winter period in
1983
Participants 50 patients from Royal Newcastle Hospital with chronic obstructive lung disease
(COPD) not taking corticosteroids or immunosuppressants
Mean age of all participants: 65.5
Interventions NTHi vaccine and 2 placebo arms (enteric-coated glucose tablets or 25 mg sodium
tauroglycocholate). 3 courses of tablets were taken at 0, 28, 56 days. Each course was 2
tablets taken before breakfast on 3 consecutive days
Outcomes 1. Number of lower respiratory infections
2. H. influenzae isolation
3. Salivary antibodies
Notes Many participants were taking antibiotics and bronchodilator agents but were not taking
steroids or immunosuppressants
Ciba Griegy (Australia) was cited for financial assistance in the discussion
Trial was conducted at the Royal Newcastle Hospital
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomisation was completed indepen-
dently by a “Dr Smith” who kept the trial
code allocations privately; how randomisa-
tion was performed has not been disclosed.
Whilst Dr Smith is not one of the trial au-
thors, the exact nature of their relationship
with the study is unknown. Randomisation
in 1 arm had a very uneven male to female
ratio
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk For each participant with an acute upper
and lower respiratory infection, an infec-
tion questionnaire was completed by doc-
tors who were not involved with the study
and had no knowledge of the patient’s test
group
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Clancy 1985 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk 1. Infection questionnaire with an
independent doctor with no knowledge of
test group
2. Sputum cultures collected to detect
H. influenzae involvement objectively
3. Blood tests collected to assess salivary
antibodies objectively
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for. 2 par-
ticipants out of the 50 originally enrolled
died during the study
Selective reporting (reporting bias) Low risk Nil
Other bias Low risk Nil
Clancy 1990
Methods Single-blind RCT
Participants 6-month study on Australians recruited during winter 1986 through radio station ad-
vertisement
Mean age of 47.4 in the vaccine arm and 46.3 in the placebo arm
Interventions Oral vaccination with killed NTHi and placebo with glucose both were enteric-coated
Outcomes 1. Total number of episodes of acute bronchitis
2. Number of episodes of acute wheezy bronchitis
3. Reduction in antibiotic use
Notes Participants assessed on admission to trial and at 3 and 6 months during the trial. Most
participants had previously unrecognised smoking-related chronic lung disease. 72%
smokers and 58%had chronic bronchitis. Participant admission criteria were > 3 episodes
of acute bronchitis (cough productive with sputum) over previous 2 years and an absence
of chronic lung disease determined at clinical interview
Trial was conducted as joint research at the Royal Newcastle Hospital and Macquarie
University
There was no disclosure of financial assistance
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants coded and randomised by an independent third
party into 2 groups. 40 participants were admitted to study; 37
completed the 6-month trial. Randomisation gave well-matched
treatment groups, which were equal at baseline measurement.
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Clancy 1990 (Continued)
There was no significant reduction in the number of participants
suffering from an episode of acute bronchitis
Allocation concealment (selection bias) High risk Participants were allocated to the intervention group based on
periods of acute bronchitis that had been assessed by a nurse
practitioner using an infection questionnaire, which may have
room for subjectivity
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Medication had the same regime and administration for both
groups. In the treatment arm given the active preparation each
tablet contained 10 x killed NTHi. The placebo arm were given
a preparation containing glucose. Both were 2 enteric-coated
tablets before breakfast on each of 3 consecutive days and re-
peated at 28 and 56 days. However, only participants were
blinded in this study (single-blinded)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk 1. A questionnaire was used to diagnose acute bronchitis
and the side effects of the vaccine, which may be subjective
according to the marker. However, the questionnaire did
include a detailed range of signs/symptoms to be supported
with routine haematological, biochemical and immunological
test results (including a throat swab and Gram staining to
validate the sputum)
2. The differentiation of a wheeze from a normal acute
bronchitis event is not clearly defined
3. Antibiotic use was measured objectively
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for. 3 participants dropped out
from the study: 2 from the placebo arm, 1 from the active arm
due to poor compliance
Selective reporting (reporting bias) Low risk Nil
Other bias Low risk Nil
Clancy 2013
Methods The study was a double-blind, placebo-controlled, prospective study for 9 months over
the Australian winter of 2011
Participants 320 moderate-severe COPD participants with FEV1 < 60% predicted were recruited
from 21 sites across Australia
Mean age of participants in the vaccine arm was 71.2 and in the placebo arm was 67.9
Interventions HI-164 oral vaccine enteric-coated tablets (2 per day) that each contained 45 mg active
substance of formalin-inactivated NTHi (HI-164)
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Clancy 2013 (Continued)
Outcomes 1. Number of moderate-severe exacerbations
2. Number of hospital admissions
3. Number of corticosteroids and antibiotics prescribed
Notes This was a multi-centre trial conducted over various health districts across Australia
The trial does not cite any financial acknowledgement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Does not disclose method. Randomisation
mentioned but technique not specified
Allocation concealment (selection bias) Unclear risk Does not disclose method. Participants as-
sumed to be blinded to the allocation pro-
cess and blinded to whether treatment or
placebo received
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded study with same adminis-
tration of medication for both treatment
and placebo arms. The treatment consisted
of 3 courses of tablets - each course was 2
tablets daily (before breakfast) for 3 con-
secutive days, with courses repeated at day
28 and day 56. Following randomisation,
participants attended site visits at weeks 4,
8, 12 and thereafter at 4-week intervals un-
til week 36. The placebo group had the
same regime, except with matched placebo
tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded study where at all visits
acute episodes and background symptoms
were recorded by a questionnaire. To doc-
ument change in day-to-day symptoms all
patients used a diary and the St George’s
Respiratory Questionnaire for COPD pa-
tients (SGRQ-C) (version 1.1; 11-12008)
was administered at visit 2 (baseline), visit
5 (week 12), visit 6 (week 24) and visit 7
(week 36)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 320 participants were the ITT population,
with a 10% drop-out rate anticipated to
ensure that greater than 270 completed the
study as required by the power analysis.
Specifically, adverse event rates were simi-
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Clancy 2013 (Continued)
lar in both groups: serious adverse events
(placebo 33.5%; active 38.5%) with 4
deaths in the active group and 2 in the
placebo group. None of these events were
considered to be due to treatment modality
Selective reporting (reporting bias) Low risk Nil
Other bias Low risk Nil
Lehmann 1991
Methods RCT of 12 months duration, double-blind, placebo-controlled
Participants Adults identified as suffering from chronic lung disease
62 participants included
Setting: PNG highlands (under study surveillance)
Recruitment: nominated
Inclusion: productive cough fitting the time criteria for chronic lung disease
Mean age of participants in the vaccine arm was 52.6 and in the placebo arm was 53.7
Interventions Oral inactivated vaccine containing 10 H. influenzae
Control: placebo, not specified
Duration: 2 tablets in the morning for 3 consecutive days at monthly intervals for 3
consecutive months
Outcomes 1. Incidence of acute exacerbations
2. Bacterial carriage
3. Adverse side effects of NTHi vaccine
Notes An acute exacerbation is defined as an increase in the volume and purulence of sputum
with no evidence of respiratory distress, with or without chest pain or fever. This defini-
tion was consolidated with clinical examination, respiratory questionnaire in Melasian
pigeon English, spirometry and sputum samples
Conducted at PNG institute of medical research. Auspharm International Ltd cited in
acknowledgements for setting up study and ongoing support
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The investigators describe appropriate ran-
dom sequence generation using a randomi-
sation code for the courses of vaccine and
placebo tablets
Allocation concealment (selection bias) Low risk Investigators enrolling participants could
not foresee assignment as randomisation
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Lehmann 1991 (Continued)
was performed by the third party “Aus-
pharm International Ltd.” in New South
Wales accounting for the concealment of
allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind trial. Blinding of participants
and key study personnel ensured and un-
likely that the blinding could have been
broken
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind trial. The outcomes assessed
in both groups were measured using the
same questionnaire and amedical examina-
tion. Methods of ensuring blinding of out-
come assessment were not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Concluded from the trial report, there is no
mention of ITT for participants lost to fol-
low-up (8 from vaccine group and 3 from
placebo group). This is substantial consid-
ering the small group sizes; it is possible
that it had an effect on the outcome
Selective reporting (reporting bias) Low risk Study report fails to include results for a
key outcome (prescription rate of antibi-
otics) that would be expected to have been
reported for such a study, although the pro-
tocol is not available. However, all primary
outcomes are reported
Other bias Low risk The study appears to be free of other
sources of bias
Tandon 1991
Methods 6-month RCT, double-blind, placebo-controlled
Participants Adultswith history of chronic bronchitiswith recurrent respiratory tract infections (RTIs)
64 patients included
Mean age vaccine group: 73.1 years; placebo group: 71.1 years
Settings: Chest Clinic, Western Australia
Inclusion: chronic bronchitis, documented recurrent RTIs, presence of H. influenzae in
sputum
Exclusion: COAD patients without recurrent RTIs, or on long-term antibiotics
Interventions The oral vaccine contained 10 killed H. influenzae
Control: placebo was a lactose substitute for bacteria
Duration: 2 tablets in the morning for 3 consecutive days monthly for 3 consecutive
months (day 0, 28, 56)
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Tandon 1991 (Continued)
Outcomes 1. Incidence and occurrence of acute infections
2. NTHi carriage
3. Number of courses of antibiotics prescribed
4. Adverse effects of the vaccine
5. Quality of life (VAS score)
Notes Acute exacerbation defined as: increase in volume and purulence of sputum usually asso-
ciated with an increase in breathlessness and/or fever requiring treatment with antibiotics
Exacerbation assessed by the trial authors with the following: physical exam, respiratory
questionnaire (ATS DLD 78), lung function via spirometry and sputum samples
Auspharm cited for providing Bronchostat and placebo tablets. Conducted at the repa-
triation hospital Western Australia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The investigators describe a randomisation
methodology in the sequence generation
process - a randomisation chart
Allocation concealment (selection bias) Low risk Investigators enrolling participants could
not foresee assignment because pharmacy-
controlled central allocation was used to
conceal allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Blinding of participants and
key study personnel ensured and unlikely
that the blinding could have been broken
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This study does not report the method
of ensuring blinding of outcome assessors.
Respiratory questionnaire was used to col-
lect data for primary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10 participants lost to follow-up (3 in
vaccine group and 7 in placebo group)
were analysed by intention-to-treat, which
showed no significant differences
For dichotomous outcome data, the pro-
portion of missing outcomes compared
with the observed event risk was not
enough to have a clinically relevant impact
on the intervention effect estimate
Selective reporting (reporting bias) Low risk The published report includes all expected
outcomes
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Tandon 1991 (Continued)
Other bias Low risk The study appears to be free of other
sources of bias
Tandon 2010
Methods 4-month double-blind, placebo-controlled RCT carried out in winter in 4 centres in
Western Australia
Participants People with severe COPD defined by FEV1 < 50% or > 2 acute exacerbations per year
for 2 consecutive years
Mean age of participants in the vaccine arm was 69.5 and in the placebo arm was 67.3
Interventions HI-1640V; each tablet contained 45 mg approximately 10 bacteria of formalin inacti-
vated NTHi provided as enteric-coated tablets
Control: enteric-coated placebo tablets containing excipients only
Duration: protocol stated that participants took 3 courses of 2 tablets in the morning
for 3 consecutive days with courses repeated at 28 and 56 days
Outcomes 1. Number and severity of acute episodes (increase in volume and purulence of sputum)
2. Antibiotic courses
3. Sputum bacteriology and immune markers
4. Hospitalisations
5. Adverse effects
Notes Multicentre trial. Most authors disclosed contributions fromHunter Immunology Lim-
ited
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were reportedly randomised
although themethod of randomisation was
not discussed. Baseline characteristics sug-
gest that randomisation was successful
Allocation concealment (selection bias) Unclear risk No information was provided about the
procedure for protecting the randomisation
process so that the treatment to be allocated
was not known before the patient was en-
tered into the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind trial
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Tandon 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Primary outcome was measured using a
respiratory questionnaire. This subjective
data are prone to recall bias. Secondary
outcomes were objectively measured using
bacterial colonisations and antibody titres
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants were followed up for 4months
after completing the 3 courses. No patients
were lost to follow-up. Data surrounding
withdrawal and discontinuation from the
study were well described
Selective reporting (reporting bias) Low risk The published report includes all expected
outcomes
Other bias Low risk No other sources of biases were identified
COAD: chronic obstructive airways disease
COPD: chronic obstructive pulmonary disease
FEV1: forced expiratory volume in one second
H. influenzae:Haemophilus influenzae
ITT: intention-to-treat
NTHi: non-typeable Haemophilus influenzae
PNG: Papua New Guinea
RCT: randomised controlled trial
RTI: respiratory tract infection
VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Clancy 2010 The participants and outcome measures of this study did not match this review’s protocol. Participants were smokers
with no clearly defined respiratory disease. Outcome measures were limited to physiological markers as opposed to
the clinical outcomes of this review
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Characteristics of studies awaiting assessment [ordered by study ID]
ACTRN12606000074594 2013
Methods Subjects will be randomly allocated to active tablets each containing 45 mg HI-1-164-AS (inactivated non-typeable
Haemophilus influenzae). Study medication (2 tablets) will be taken on days 1, 2, 3, 29, 30, 31, 57, 58, 59. The live
phase of the study will be of 8 months duration (March to October)
Participants Both males and females, greater than or equal to 18 years of age, with moderate to severe airway disease
Total number of participants is 124; randomised to either active or placebo groups
Interventions HI-1-164-AS (inactivated non-typeable Haemophilus influenzae) oral vaccine tablet
Outcomes Primary outcomes: number of episodes of acute bronchitis during the study; proportion of participants experiencing
an episode of acute bronchitis during the study; duration of episodes of acute bronchitis during the study; number
of courses of antibiotics taken for treatment of acute episodes of bronchitis during the study
Secondary outcomes: NTHi-specific antibody; pharyngeal colonisation with Haemophilus influenzae (H. influenzae);
presence of H. influenzae, M. catarrhalis, S. pneumoniae and Pseudomonas species in sputum; severity of episodes of
acute bronchitis
Notes It was planned in this trial that the analysis of the severity of episodes of acute bronchitis was to be based on the
respiratory questionnaires completed by the patients at the time of each episode. However, insufficient respiratory
questionnaires were completed during the study to allow for analysis of the data collected. In accordance with recent
draft guidance for industry for developing drugs for treatment of COPD issued by the FDA in November 2007,
assessment of modification or prevention of exacerbations of disease can include severity of exacerbations as a primary
efficacy endpoint. This can be based on worsening of symptoms requiring changes in treatment or requiring urgent
treatment or hospitalisation. On a post hoc basis, rates of hospitalisation, corticosteroid use and a review of the
medications used to treat the episodes of acute bronchitis were all analysed as measures of severity of episodes
ACTRN12606000076572 2013
Methods Participants will be randomly allocated to active tablets each containing 45 mg HI-1-164-AS (inactivated non-
typeable Haemophilus influenzae). Study medication (2 tablets) will be taken on days 1, 2, 3, 29, 30,31, 57, 58, 59.
The live phase of the study will be of 8 months duration (March to October)
Participants Both males and females, greater than or equal to 18 years of age, with mild to severe airway disease
Total number of participants is 124; randomised to either active or placebo groups
Interventions HI-1-164-AS (inactivated non-typeable Haemophilus influenzae) oral vaccine tablet
Outcomes Primary outcomes: number of episodes of acute bronchitis during the study; proportion of participants experiencing
an episode of acute bronchitis during the study; duration of episodes of acute bronchitis during the study; number
of courses of antibiotics taken for treatment of acute episodes of bronchitis during the study
Secondary outcomes: NTHi-specific antibody; pharyngeal colonisation with Haemophilus influenzae (H. influenzae);
presence of H. influenzae, M. catarrhalis, S. pneumoniae and Pseudomonas species in sputum; severity of episodes of
acute bronchitis
Notes This trial is synonymous to ACTRN12606000074594 2013, with the only difference to be found in the inclusion
criteria of participants; this trial accepts patients with mild to severe airway disease (versus moderate to severe),
however, there is no further specification or discussion on how the investigators discern the extent of airway disease
in their participants. Both studies enrolled participants on 7 March 2006 and were conducted simultaneously
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ACTRN12610000916044 2013
Methods Participants will be asked to take the study medication on 3 consecutive days each month for the first 3 months (that
is, 9 doses in total). Each daily dose of HI-164OV contains 90 mg of HI-164 and will be taken orally approximately
1 hour prior to breakfast
Participants Both males and females, from 40 to 85 years of age, with moderate to severe COPD
Total number of participants is 340; randomised to either active or placebo groups
Interventions Oral vaccine tablet containing 45 mg HI-164 active product
Outcomes Primary outcomes: the primary endpoint is the rate of exacerbations requiring oral/parenteral corticosteroid treatment
or hospitalisation. Patients will maintain daily diaries to record the severity of respiratory symptoms and the need for
medications. Episodes of acute exacerbations, medication usage and COPD-related clinic or hospital visits will be
recorded at each study visit. The rate of exacerbations will be measured in number of days since study entry to start
of treatment or hospitalisation
Secondary outcomes: proportion of participants per group experiencing exacerbations requiring oral/parenteral corti-
costeroid treatment or hospitalisation since study entry; time to systemic corticosteroid use or hospitalisation, or time
to antibiotic use (separately and collectively) as measured in number of days from study entry to start of treatment;
usage of antibiotics over the course of the study measured as total days usage, total number of courses and number
of acute exacerbation events requiring 3 or more courses of antibiotics; use of oral/parenteral corticosteroid therapy
for COPD exacerbations as measured by the total number of courses and total number of days of usage since study
entry; total number of acute COPD exacerbations defined as mild, moderate or severe
Notes Acute COPDexacerbations are defined as sustained (2 ormore days) worsening or newonset of respiratory symptoms,
particularly cough, purulent sputum and breathlessness, from steady state and beyond normal day to day variation
that is acute in onset and necessitates a change in medication. Severity of exacerbations is based on the GOLDCOPD
classification of severity.
Proportionof participants having recurrent (more than 1)COPDexacerbation. Acute exacerbationswill be considered
distinct events if onset dates are 7 or more days after resolution of symptoms defining the previous exacerbation;
severity of acute exacerbations (mild, moderate or severe) based on the GOLDCOPD classification system. Duration
of acute COPD exacerbations in number of days from onset until resolution of symptoms. The duration in number
of days of moderate and severe COPD exacerbations. The number and duration of hospitalisations, measured as
total number of hospitalisations since study entry, total number of days per hospitalisation and total number of days
hospitalisation since study entry. Total number of unscheduled visits to a physician and to the emergency department
due to a COPD exacerbation since study entry. Change in forced expiratory volume in one second (FEV1) from
study entry based on spirometry (lung function test) measurement at each study visit. Change in quality of life based
on the St George’s Respiratory Questionnaire for COPD patients. Safety of HI-164OV based on adverse events (e.
g. nausea, diarrhoea), vital signs (blood pressure, pulse, respiration rate), ECG and laboratory results
COPD: chronic obstructive pulmonary disease
ECG: electrocardiogram
FDA: Food and drug administration (United States)
GOLD: global initiative for chronic obstructive lung disease; organisation responsible for classifying and defining stages of COPD
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D A T A A N D A N A L Y S E S
Comparison 1. Primary outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbations (number of
exacerbations/person)
6 557 Rate Ratio (Fixed, 95% CI) 0.97 [0.84, 1.12]
2 Mortality (deaths during trial
period)
5 518 Odds Ratio (M-H, Fixed, 95% CI) 1.62 [0.63, 4.12]
Comparison 2. Secondary outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Prescriptions (number of
courses/person/year)
3 142 Rate Ratio (Fixed, 95% CI) 1.81 [1.35, 2.44]
2 Hospital admissions (number of
patients hospitalised during
trial period)
2 358 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.13, 7.04]
3 Adverse events (number of
adverse events/person)
4 484 Rate Ratio (Fixed, 95% CI) 1.43 [0.70, 2.92]
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Analysis 1.1. Comparison 1 Primary outcomes, Outcome 1 Exacerbations (number of
exacerbations/person).
Review: Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease
Comparison: 1 Primary outcomes
Outcome: 1 Exacerbations (number of exacerbations/person)
Study or subgroup Vaccine Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Clancy 1985 17 16 -2.626 (1.038) 0.5 % 0.07 [ 0.01, 0.55 ]
Clancy 1990 20 20 -0.531 (0.398) 3.5 % 0.59 [ 0.27, 1.28 ]
Tandon 1991 31 33 -0.309 (0.257) 8.3 % 0.73 [ 0.44, 1.21 ]
Lehmann 1991 30 32 -0.241 (0.259) 8.2 % 0.79 [ 0.47, 1.31 ]
Tandon 2010 18 20 -0.174 (0.281) 7.0 % 0.84 [ 0.48, 1.46 ]
Clancy 2013 160 160 0.081 (0.087) 72.6 % 1.08 [ 0.91, 1.29 ]
Total (95% CI) 276 281 100.0 % 0.97 [ 0.84, 1.12 ]
Heterogeneity: Chi2 = 11.57, df = 5 (P = 0.04); I2 =57%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours vaccine Favours placebo
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Analysis 1.2. Comparison 1 Primary outcomes, Outcome 2 Mortality (deaths during trial period).
Review: Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease
Comparison: 1 Primary outcomes
Outcome: 2 Mortality (deaths during trial period)
Study or subgroup Vaccine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Clancy 1985 0/17 2/17 34.4 % 0.18 [ 0.01, 3.98 ]
Clancy 2013 4/160 2/160 27.6 % 2.03 [ 0.37, 11.22 ]
Lehmann 1991 3/30 1/32 12.3 % 3.44 [ 0.34, 35.09 ]
Tandon 1991 3/31 0/33 6.1 % 8.23 [ 0.41, 166.09 ]
Tandon 2010 0/18 1/20 19.6 % 0.35 [ 0.01, 9.18 ]
Total (95% CI) 256 262 100.0 % 1.62 [ 0.63, 4.12 ]
Total events: 10 (Vaccine), 6 (Placebo)
Heterogeneity: Chi2 = 4.38, df = 4 (P = 0.36); I2 =9%
Test for overall effect: Z = 1.00 (P = 0.31)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours vaccine
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Analysis 2.1. Comparison 2 Secondary outcomes, Outcome 1 Prescriptions (number of
courses/person/year).
Review: Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease
Comparison: 2 Secondary outcomes
Outcome: 1 Prescriptions (number of courses/person/year)
Study or subgroup Vaccine Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Clancy 1990 20 20 0.397 (0.754) 4.0 % 1.49 [ 0.34, 6.52 ]
Tandon 1991 31 33 0.501 (0.187) 64.9 % 1.65 [ 1.14, 2.38 ]
Tandon 2010 18 20 0.817 (0.27) 31.1 % 2.26 [ 1.33, 3.84 ]
Total (95% CI) 69 73 100.0 % 1.81 [ 1.35, 2.44 ]
Heterogeneity: Chi2 = 1.00, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.95 (P = 0.000078)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
More scripts for vaccine More scripts for placebo
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Analysis 2.2. Comparison 2 Secondary outcomes, Outcome 2 Hospital admissions (number of patients
hospitalised during trial period).
Review: Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease
Comparison: 2 Secondary outcomes
Outcome: 2 Hospital admissions (number of patients hospitalised during trial period)
Study or subgroup Vaccine Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Clancy 2013 80/160 48/160 56.6 % 2.33 [ 1.47, 3.69 ]
Tandon 2010 3/18 8/20 43.4 % 0.30 [ 0.07, 1.38 ]
Total (95% CI) 178 180 100.0 % 0.96 [ 0.13, 7.04 ]
Total events: 83 (Vaccine), 56 (Placebo)
Heterogeneity: Tau2 = 1.78; Chi2 = 6.36, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
More vaccine admissions More placebo admissions
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Analysis 2.3. Comparison 2 Secondary outcomes, Outcome 3 Adverse events (number of adverse
events/person).
Review: Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease
Comparison: 2 Secondary outcomes
Outcome: 3 Adverse events (number of adverse events/person)
Study or subgroup Vaccine Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Clancy 2013 160 160 1.099 (1.153) 9.9 % 3.00 [ 0.31, 28.76 ]
Lehmann 1991 30 32 0.756 (1.225) 8.8 % 2.13 [ 0.19, 23.50 ]
Tandon 1991 31 33 0.161 (0.474) 58.7 % 1.17 [ 0.46, 2.97 ]
Tandon 2010 18 20 0.392 (0.764) 22.6 % 1.48 [ 0.33, 6.62 ]
Total (95% CI) 239 245 100.0 % 1.43 [ 0.70, 2.92 ]
Heterogeneity: Chi2 = 0.69, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
More events in placebo More events in vaccine
A D D I T I O N A L T A B L E S
Table 1. Rate estimates of acute exacerbations across included studies
Study Vaccinated Placebo Absolute rate difference
Clancy 1985 0.256 0.272 0.016 (-)
Clancy 1990 1.000 1.700 0.700 (-)
Clancy 2013 0.717 0.767 0.050 (-)
Lehmann 1991 0.800 1.210 0.410 (-)
Tandon 1991 3.355 4.364 1.009 (-)
Tandon 2010 3.667 4.350 0.683 (-)
Overall mean 1.633 2.111 0.478 (-)
Estimated rate of exacerbation calculated as number of exacerbations per person per year.
Refer to Analysis 1.1: Forest plot comparison and rate ratios for exacerbations.
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Table 2. Rate estimates of antibiotic prescriptions across included studies
Study Vaccinated Placebo Absolute rate difference
Clancy 1990 0.500 1.200 0.700 (-)
Tandon 1991 5.806 10.194 4.388 (-)
Tandon 2010 3.180 7.200 4.020 (-)
Overall mean 3.162 6.198 3.036 (-)
Estimated rate of antibiotic prescriptions calculated as number of antibiotic courses per person per year.
Refer to Analysis 2.1: Forest plot comparison and rate ratios for antibiotic prescriptions.
Table 3. Rate estimates of adverse events across included studies
Study Vaccinated Placebo Absolute rate difference
Clancy 2013 0.008 0.025 0.017 (-)
Lehmann 1991 0.067 0.031 0.036 (+)
Tandon 1991 1.032 1.212 0.180 (-)
Tandon 2010 0.167 0.450 0.283 (-)
Overall mean 0.319 0.430 0.111 (-)
Estimated rate of adverse events calculated as number of adverse events per person per year.
Refer to Analysis 2.3: Forest plot comparison and rate ratios for adverse events.
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A P P E N D I C E S
Appendix 1. MEDLINE and CENTRAL search strategy
MEDLINE (Ovid)
1 exp Bronchitis/
2 bronchit*.tw.
3 exp Pulmonary Disease, Chronic Obstructive/
4 (chronic obstructive pulmonary disease* or chronic obstructive lung disease*).tw.
5 Lung Diseases, Obstructive/
6 (copd or aecb).tw.
7 or/1-6
8 exp Haemophilus influenzae/
9 (haemophilus influenz* or “h. influenzae”).tw.
10 (hemophilus or haemophilus).tw.
11 nthi.tw.
12 or/8-11
13 exp Vaccines/
14 exp Immunization/
15 Immunotherapy/
16 (vaccin* or immuni* or inoculat*).tw.
17 or/13-16
18 12 and 17
19 Haemophilus Vaccines/
20 18 or 19
21 7 and 20
Appendix 2. EMBASE (Elsevier) search strategy
#27 #18 AND #26
#26 #21 NOT #25
#25 #22 NOT #24
#24 #22 AND #23
#23 ’human’/de
#22 ’animal’/de OR ’nonhuman’/de OR ’animal experiment’/de
#21 #19 OR #20
#20 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR allocat*:ab,ti OR trial:ti OR (doubl* NEXT/1
blind*):ab,ti
#19 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#18 #5 AND #17
#17 #15 OR #16
#16 ’haemophilus vaccine’/de
#15 #9 AND #14
#14 #10 OR #11 OR #12 OR #13
#13 vaccin*:ab,ti OR immuni*:ab,ti OR inoculat*:ab,ti
#12 ’immunotherapy’/de
#11 ’immunization’/exp
#10 ’vaccine’/exp
#9 #6 OR #7 OR #8
#8 haemophilus:ab,ti OR hemophilus:ab,ti
#7 ’haemophilus influezae’:ab,ti OR ’h. influenzae’:ab,ti OR nthi:ab,ti
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#6 ’haemophilus influenzae’/exp
#5 #1 OR #2 OR #3 OR #4
#4 ’chronic obstructive lung disease’:ab,ti OR ’chronic obstructive pulmonary disease’:ab,ti OR copd:ab,ti OR aecb:ab,ti
#3 ’chronic obstructive lung disease’/de
#2 bronchit*:ab,ti
#1 ’bronchitis’/exp
Appendix 3. CINAHL (Ebsco) search strategy
S18 S6 and S17
S17 S15 or S16
S16 (MH “HIB Vaccine”)
S15 S9 and S14
S14 S10 or S11 or S12 or S13
S13 TI (vaccin* or immuni* or inocul*) OR AB (vaccin* or immuni* or inocul*)
S12 (MH “Immunotherapy”)
S11 (MH “Immunization+”)
S10 (MH “Vaccines+”)
S9 S7 or S8
S8 TI (haemophilus or hemophilus or “h. influenzae” or nthi) OR AB (haemophilus or hemophilus or “h. influenzae” or nthi)
S7 (MH “Haemophilus Influenzae”)
S6 S1 or S2 or S3 or S4 or S5
S5 TI (chronic obstructive pulmonary disease* or chronic obstructive airway* disease* or chronic obstructive lung disease* or coad
or copd or aecb) OR AB (chronic obstructive pulmonary disease* or chronic obstructive airway* disease* or chronic obstructive lung
disease* or coad or copd or aecb)
S4 (MH “Lung Diseases, Obstructive”)
S3 (MH “Pulmonary Disease, Chronic Obstructive+”)
S2 TI bronchit* OR AB bronchit*
S1 (MH “Bronchitis+”)
Appendix 4. LILACS (BIREME) search strategy
Search > (MH:Bronchitis ORMH:C08.127.446$ ORMH:C08.381.495.146$ ORC08.730.099$ OR Bronquitis OR Bronquite OR
bronchit$ ORMH:“Pulmonary Disease, Chronic Obstructive” OR “Chronic Obstructive Airway Disease” OR “Chronic Obstructive
Lung Disease” OR “Chronic Obstructive Pulmonary Disease” ORCOADORCOPDORMH:C08.381.495.389$ OR “Obstrucción
Crónica del Flujo Aéreo” OR “Obstrucción del Flujo Aéreo Crónica” OR “Enfermedad Obstructiva Crónica de las Vías Aéreas”
OR “Enfermedad del Pulmón Crónica Obstructiva” OR “Enfermedad Pulmonar Crónica Obstructiva” OR EVOC OR EPOC OR
“Neumopatía Obstructiva Crónica” ORDPOCOR “Obstrução Crônica do Fluxo Respiratório” OR “Obstrução do Fluxo Respiratório
Crônica” OR “Doença Obstrutiva Crônica das Vias Aéreas” OR “Doença Obstrutiva Crônica do Pulmão” OR “Doença Obstrutiva
Crônica Pulmonar” OR MH:“Lung Diseases, Obstructive” OR AECB) AND (((MH:“Haemophilus influenzae” OR “H. influenzae”
OR haemophilus OR hemophilus OR nthi ORMH:B03.440.450.600.450.330$ ORMH:B03.660.250.550.290.330$) AND (MH:
Vaccines OR Vacunas OR Vacinas OR vaccin$ OR D20.215.894$ OR MH:Immunization OR Inmunización OR Imunização OR
MH:E02.095.465.425.400$ OR MH:E05.478.550$ OR MH:N02.421.726.758.310$ OR MH:N06.850.780.200.425$ OR MH:
N06.850.780.680.310$ORMH:SP2.026.182.113$ORMH:SP4.001.002.015.049$ORMH:SP8.946.819.838$OR“Estimulación
Inmunológica” OR Inmunoestimulación OR “Sensibilización Inmunológica” OR Variolación OR Variolización OR Inmunizaciones
OR“Estimulação Imunológica”ORImunoestimulaçãoOR“Sensibilização Imunológica”ORVariolaçãoORImunizaçõesOR immuni$
ORMH:Immunotherapy OR Inmunoterapia OR Imunoterapia OR inocul$)) OR (MH:“Haemophilus Vaccines” OR “Vacunas contra
Haemophilus” OR “Vacinas Anti-Haemophilus”))
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Appendix 5. Web of Science (Thomson Reuters) search strategy
# 5 18 #4 AND #3
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
# 4 1,371,720 Topic=(random* or placebo* or “clinical trial*” or ((singl* or doubl*) NEAR/1 blind*) or allocat* or crossover*
or “cross over”) OR Title=(trial*)
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
# 3 117 #2 AND #1
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
# 2 5,029 Topic=(hemophilus or haemophilus or “h. influenzae” or nthi) AND Topic=(vaccin* or immuni* or inocul*)
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
# 1 42,910 Topic=(bronchit* or “chronic obstructive pulmonary disease*” or “chronic obstructive airway* disease*” or
“chronic obstructive lung disease*” or coad or copd or aecb)
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
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All of the authors contributed to the drafting of the protocol. Professor Mieke van Driel and Professor Allan Cripps provided expert
and methodological advice, including extensive help and support during the drafting of the protocol and review.
D E C L A R A T I O N S O F I N T E R E S T
Professor Allan Cripps was involved in the initial animal work and conduct of the four trials in Newcastle, Australia. The commercial
product, ’Bronchostat’, which originated from these trials, is no longer commercially available. The commercial companies Auspharm
International Limited and subsequently Cortecs International Limited have ceased trading and were delisted from the Australian Stock
Exchange (ASX) in 1991 and 1998 respectively. Prior to 1996, Professor Cripps acted as a consultant for both Auspharm International
Limited and Cortecs International Limited. Hunter Immunology Limited subsequently continued development of the oral whole cell
vaccine (HI-164). In 2004 Professor Cripps acquired a small stock holding in the company. In 2011, Hunter immunology Limited
was acquired by Bioxyne Limited and his shares were transferred to Bioxyne Limited. Subsequently, in February 2014 Bioxyne Limited
sold to Mariposa Health Limited, the HI-164 Oral Vaccine project and all associated intellectual property. Should Mariposa Health
Limited successfully commercialise the vaccine, Mariposa Health Limited have agreed to pay Bioxyne Limited a Royalty of up to 6.5%
of gross revenue. Professor Cripps retains a small residual stock holding in Bioxyne Limited. Professor Cripps has no stock holding in
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Risk ratios have been included as a method of measuring the treatment effect for dichotomous data given as rates. We have amended
the Data synthesis to reflect that we have also used the fixed-effect model to pool study data that reported events as rates.
Prescriptions of corticosteroids were not an outcome measure in any of the included studies and therefore not part of this review’s
analyses. However, patients were noted to have been prescribed steroids prior to commencing the trial and may have continued steroids
or have been further prescribed steroids during the trial periods without clear reporting in the studies (this is discussed in the Summary
of main results).
Number of hospital admissions was added to Secondary outcomes as part of the assessment of the severity of exacerbations after post
hoc analysis revealed that a number of studies reported hospital admissions.
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